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Early detection of Alzheimer’s disease (AD) allows patients and families extended time 
for care planning, often facilitated by social workers. Detection methods are continually 
improving as research efforts focus on creating more reliable and valid diagnostic tests across 
dementia types. Imaging amyloid in the brain, a hallmark of AD, may allow for the detection of 
AD pathology before memory symptoms are noticeable, or at the earliest stages of illness. 
Although social workers provide critical support to patients and families throughout the 
diagnostic process and the progression of illness, social work research has yet to substantially 
address dementia diagnostic technologies and their potential to impact care management 
approaches. 
This dissertation explores what biopsychosocial factors, including demographic, cognition, 
health, and family-related factors, are associated with amyloid imaging (AI) research interest for 
AD, for those with varied levels of cognitive impairment, as well as for individuals with 
dementia (IWDs). Applying a biopsychosocial framework to the investigation of who seeks to 
use such technologies, and – possibly more importantly - who misses out, brings a social work 
perspective to this research area. Using a secondary data sample extracted from registry data of 
an Alzheimer Disease Center, multinomial logistic regression was used to model biopsychosocial 
factors associated with differing levels of AI research interest and participation.  
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For the full sample, younger age, better cognition, and experience of cognitive diagnostic 
change were related to both AI interest and participation. For IWDs, absence of medical 
comorbidity and having a spousal or partner care relationship were associated with AI interest 
and participation. Participation in diagnostic disclosure, and the receipt of extended social work 
support, points to the critical role social workers may play in facilitating amyloid imaging 
research participation. Older age groups and those with more impaired cognition may benefit 
from tailored counseling approaches that address concerns and needs. For IWDs, medical 
comorbidity may create a barrier to seeking AI, while the significance of spousal and partner 
care relationships intimates that these care partners have more time to devote to AI. These 
findings support social work roles in multidisciplinary dementia care teams using AI, and enrich 
the content of AI counseling protocols by identifying participant-specific factors that impact AI 
participation.  
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1.0  INTRODUCTION 
 
James Watson, who won a Nobel Prize for discovering the structure of DNA, agreed to 
be the very first person to complete gene sequencing. He had just one condition: "I didn't want to 
know its prediction for Alzheimer's. There's nothing you can do to prevent it, so why would you 
want to know?" 
     -Morning Edition, National Public Radio, 2012 
1.1 PURPOSE OF THE STUDY 
We are experiencing a dynamic time in research on Alzheimer’s disease (AD) - a progressive 
and devastating illness for which currently no cure exists. Diagnostic methods for dementia, in 
particular, are improving as research efforts focus on creating more reliable and valid diagnostic 
tests across dementia types. One such method uses positron emission tomography (PET) and an 
intravenous compound to image amyloid in the brain – a hallmark of AD. This type of imaging 
may be able to detect amyloid in the brain before memory symptoms are noticeable or at the 
earliest stages of illness. When and how to counsel individuals on the use of such testing has 
only just begun to be considered, and have focused on their use in research settings (Lingler & 
Klunk, 2013; Roberts, Dunn, & Rabinovici, 2013). Most work has examined AI testing through a 
medical model lens. Just one pilot study has examined patient and family views regarding the AI 
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testing counseling approaches, as well as the personal utility attributed to such testing (Lingler et 
al., 2015).  
Additionally, although social workers provide a substantial amount of support to patients 
and families throughout the diagnostic process and the progression of illness - and are especially 
intrinsic to the care process given the current limitations of medical treatments - social work 
research has yet to substantially address dementia diagnostic technologies and their potential 
impact on care management approaches. Applying a biopsychosocial framework to the 
investigation of who seeks to use such technologies, and – possibly more importantly - who 
misses out, brings a social work perspective to this research area and informs social work 
practice with adults facing cognitive impairment and their families. In particular, acknowledging 
that variations in participant interest for amyloid imaging exist imports the social work tenet of 
self-determination in care decision-making into these changing and emerging care protocols for 
dementia.  
As Dr. Watson’s opening quote implies, interest in biomarker testing likely differs across 
individuals, and for varying reasons, which are not understood. This dissertation explores what 
factors are associated with interest in amyloid imaging research for Alzheimer’s disease; for 
those with varied levels of cognitive impairment, as well as for individuals diagnosed with 
dementia. Individuals with comprehensive cognitive assessment data from standardized 
measures comprise the sample and include a subsample of individuals with dementia, those who 
were the initial focus of amyloid imaging research. Using a secondary data sample extracted 
from the University of Pittsburgh Alzheimer Disease Research Center (ADRC) database, 
multinomial logistic regression was used to model biopsychosocial factors associated with 
differing levels of interest in AI research participation. A second set of binomial regression 
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modeling examines biopsychosocial factors associated with participation in AI research. The 
following objectives are the focus of this dissertation: 
• Among all ADRC participants, examine factors (demographic, cognition, health, 
dementia family history) that are associated with level of interest in brain imaging 
research; 
• Among  all ADRC participants, examine factors (demographic, cognition, health, 
dementia family history) that are associated with participation in amyloid imaging; 
• Among the ADRC participants diagnosed with dementia, examine factors (demographic, 
cognition, health, dementia family history, and care partner relationship) that are 
associated with level of interest in brain imaging research; and 
• Among the ADRC participants diagnosed with dementia, examine factors (demographic, 
cognition, health, dementia family history, and care partner relationship) that are 
associated with participation in amyloid imaging research. 
 
Differing levels of interest in AI were captured using the following categories: 1) AI 
participants (Participators); 2) individuals who declined AI participation but indicated interest in 
imaging studies (Avoiders); and 3) individuals who indicated they did not want to be contacted 
for imaging studies (Refusers). Refusers and Avoiders were aggregated to one group, Non-
Participators, and compared to Participators. For the full ADRC sample, the following factors 
were included in analysis and compared across AI interest groups and AI Participator/Non-
Participator groups: 1) demographic characteristics (age, race, gender, and education); 2) 
neurocognitive status (ADRC diagnosis, Mini-Mental State Exam Score, change in ADRC 
diagnosis); 3) health (presence of psychiatric diagnosis, presence of physical health 
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comorbidity); 4) family history of dementia (participant report of immediate relatives with 
dementia). For ADRC patient with dementia, the following factors were examined: 1) 
demographic characteristics (age, race, gender, and education); 2) neurocognitive status (Mini-
Mental State Exam Score, age at onset of cognitive symptoms); 3) health (presence of 
psychiatric diagnosis, presence of physical health comorbidity); 4) family history of dementia 
(participant report of immediate relatives with dementia); and 5) care partner relationship. This 
chapter presents a rationale for investigating participation in amyloid imaging, and its relevance 
to social work practice.  
1.2 BACKGROUND AND SIGNIFICANCE 
Access to amyloid testing has been mainly limited to research settings where, per protocol and 
due to concerns about lack of clinical significance of the results gained from findings, results 
have not been provided to participants.  However, investigating AI interest within this population 
is an important starting point because this group represents the early adopters, those that will be 
the first to be approached about the potential for receiving results, as well as those most likely to 
express interest in results. A recent study comparing interest in cognition-focused research 
results disclosure between a sample of cognitively intact individuals who had been registry 
participants in an Alzheimer Disease Center (ADC) and a general population sample reported 
that the ADC sample expressed significantly more interest in disclosure than the general 
population, even when the risks and benefits of disclosure were enumerated and discussed 
(Gooblar, Roe, Selsor, Gabel, & Morris, 2015). The ADRC registry additionally provides a 
substantially-sized sample with a range of cognitive diagnoses and a dataset using uniform, 
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standardized measures that are not readily available from clinical settings. This work lays initial 
groundwork for understanding patient acceptance of amyloid imaging in clinical practice 
settings, which has not been examined to date.  
While literature examining participation in genetic susceptibility testing for AD (e.g. 
Green et al., 2009; Roberts, 2000; Roberts et al., 2004) and memory screening and cognitive 
evaluation (e.g. Boustani et al., 2011; Werner & Heinik, 2004) provide a basis for understanding 
how demographics, cognition, and health relate to AI research interest, no studies have 
quantitatively explored whether there are biopsychosocial factors that may influence interest in 
neuroimaging. Additionally, most studies that explore factors impacting interest in genetic or 
cognitive testing for AD rely on the presentation of hypothetical scenarios to study participants, 
rather than examine true uptake of such diagnostic tools. As later described, interest reported in 
relation to hypothetical scenarios may not accurately reflect the percentages of actual utilization, 
or the factors associated with such participation. This dissertation will examine what 
demographic, cognition-related, health-related, and family-related factors, are associated with 
real participation in AI, rather than hypothetical use.  
Also differing from previous studies, three levels of interest in brain imaging will be 
modeled using multinomial logistic regression. Previous studies have only reported findings 
using a dichotomous outcome variable, as in the genetic testing and memory screening literature. 
These three levels of interest will help to tease out whether differences do exist between those 
who express interest in neuroimaging (paralleling intent or willingness to test studies) and actual 
participation.  
Overall, the increasing prevalence of this progressive and terminal illness warrants the 
need for an examination of diagnostic tools that may determine whether AD hallmark pathology 
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can be detected in the brain. Early detection means individuals have an opportunity to: 1) make 
decisions about care and service needs with support from family and care providers; 2) enroll in 
medication and other clinical trials; 3) create financial and health care advance directives; 4) 
consider safety issues in advance, such as driving; and 5) better allow for determining whether 
symptomatology is caused by a reversible process, such as depression or thyroid issues 
(Alzheimer's Association, 2011). Social workers offer integral coordination and support across 
these domains of care. Additionally, as more effective and preventative treatments develop, 
social workers may aid in the process of identifying those who will most benefit from detection 
technologies, including amyloid imaging. 
Recommendations for who should complete AI have primarily focused on clinical 
presentation as the primary consideration and several research groups have presented thoughtful 
and varying considerations of who should be given results from amyloid testing, and what 
information should be presented (e.g. Grill, Johnson, & Burns, 2013; Lingler & Klunk, 2013; 
Roberts, Dunn, & Rabinovici, 2013). They additionally acknowledge that the information 
derived from amyloid testing, including its predictive value, or information regarding the risk of 
development of AD, remains sketchy (Roberts, Dunn, & Rabinovici, 2013). Clinicians involved 
in studies using amyloid imaging voice varied opinions about providing test results, though there 
is general agreement that patients need to have say in whether test results are revealed (Shulman, 
Harkings, Green & Karlawish, 2013). It is important to note that clinical recommendations are 
only just emerging regarding the diagnostic presentations that would warrant amyloid imaging 
(Johnson et al., 2013) and for disclosing AI results (Lingler, Roberts, Schulz & Klunk, 2012) 
which remain to be influenced by scientific additions to our understanding of the implications of 
a positive amyloid finding. Therefore the question of which participants actually consent to 
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uptake is important to tease out, as it provides an understanding of whether those individuals 
deemed to benefit from AI are in fact pursuing, and receiving, access.  
As Dr. Watson’s quote implies above, interest in biomarker testing likely differs across 
patients and may be influenced by many factors. Understanding who participates in diagnostic 
testing, such as AI, can help researchers better understand the decision-making process that 
individuals tackle in response to the opportunity for diagnostic testing. This process may be 
driven by personal characteristics, such as psychological status, perceptions surrounding family 
history, and cognition and health factors. Taking the impact of these factors into account will aid 
in tailoring social work-inclusive counseling protocols to address the concerns of individuals 
who express hesitancy regarding AI participation. As social workers play critical roles in 
diagnostic disclosure and care management post diagnosis, their role facilitating in AI counseling 
should be a point of key consideration.  
1.3 RESEARCH QUESTIONS AND HYPOTHESES 
This study examined the factors associated with two domains of interaction with amyloid 
imaging: interest and participation of individuals who have completed a cognitive assessment for 
memory impairment. Each domain was examined among a sample of ADRC participants, and 
again among ADRC participants diagnosed with dementia. The following research questions and 
hypotheses were the focus of this dissertation: 
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Q.1 What factors are associated with level of interest in brain imaging among ADRC 
participants? 
H.1 Individuals who express greater interest in participation in brain imaging research: 
1) are younger; 2) have less cognitive impairment (via ADRC diagnosis and/or Mini-Mental 
State Exam score); 3) have experienced a change in cognition diagnosis; 4) have more physical 
health comorbidity; 5) have a psychiatric diagnosis; and 6) have a family history of dementia; 
when controlling for sex, race and education level. 
 
Q.2  What factors are associated with participation in amyloid imaging research among 
ADRC participants? 
H.2 Individuals who participate in amyloid imaging research: 1) are younger; 2) have 
less cognitive impairment (via ADRC diagnosis and/or Mini-Mental State Exam score); 3) have 
experienced a change in cognition diagnosis; 4) have more physical health comorbidity; 5) have 
a psychiatric diagnosis; and 6) have a family history of dementia; when controlling for sex, race 
and education level. 
 
Q.3 What factors are associated with level of interest in brain imaging research among 
ADRC participants diagnosed with dementia? 
H.3 Individuals with dementia who express greater interest in brain imaging research: 
1) are younger; 2) have less cognitive impairment (Mini-Mental State Exam score); 4) have more 
physical health comorbidity; 5) have a psychiatric diagnosis; 6) have a family history of 
dementia; and 7) have spousal/partner care support; when controlling for sex, race and education 
level. 
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Q.4 What factors are associated with participation in amyloid imaging research among 
ADRC participants diagnosed with dementia? 
 H.4 Individuals with dementia who participate in amyloid imaging research: 1) 
are younger; 2) have less cognitive impairment (Mini-Mental State Exam score); 4) have more 
physical health comorbidity; 5) have a psychiatric diagnosis; 6) have a family history of 
dementia; and 7) have a spousal/partner care support; when controlling for sex, race and 
education level. 
1.4 SIGNIFICANCE TO SOCIAL WORK PRACTICE AND RESEARCH 
Gaining an understanding of who agrees to diagnostic testing lays the groundwork for 
identifying the rationale behind interest in biomarker testing for AD and opens avenues for 
targeted, social work-inclusive interventions that may address the concerns of those pursuing AI, 
as well as those who opt out of its use. It informs the current multidisciplinary approach to 
assessment, diagnosis, and treatment planning in which social work is an integral part of the care 
team. The current investigation is the first known social work-based study to explore uptake of 
amyloid imaging. Examining the use of such diagnostic testing from a social work perspective 
grounds this research in a social work model of care and promotes social work as a key leader in 
the advancement of this research. 
Many of the factors explored here that likely influence patient and family decision-
making regarding diagnostic testing also comprise the components of a social work assessment, 
follow the biopsychosocial model of care, and fit well within the established frameworks for 
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diagnostic disclosure protocols and genetic counseling procedures. Social workers already play a 
significant role in AD care, across the domains of assessment, diagnosis, and care planning. 
Within Alzheimer Disease Research Centers, social workers partner with physicians in 
delivering the diagnosis, supporting the patient and family through the process of understanding 
the potential implications of the diagnosis, and linking individuals to appropriate services. Given 
the limitations of the current anti-dementia treatments on the market, psychosocial support and 
service planning provided by social workers may be the most critical points of care post 
diagnosis. Therefore, the social work profession naturally extends itself to involvement in the 
protocol development, assessment and utilization of pre and post counseling for dementia 
biomarker testing, as well as follow-up care. 
Shifting care models, including partnerships between primary care practices and memory 
clinics (Callahan et al., 2011) and the adoption of the medical home model for dementia care 
within these partnerships (Boustani et al., 2005; Callahan et al., 2006; French et al., 2014) all 
apply a patient-centered, collaborative care approach to dementia in a primary care setting. The 
objective of this model for dementia care is to improve screening, diagnosis and treatment in the 
primary care setting, with support from a multidisciplinary memory care staff, inclusive of social 
workers. Although current recommendations advise that amyloid imaging is not indicated in the 
routine assessment process that a primary care provider would employ (Geldmacher & Kerwin, 
2013), this emerging dementia medical model is a fitting home for AD biomarker testing, 
including amyloid imaging, with pre- and post-counseling protocols melded into existing 
processes for assessment, diagnosis, and follow-up. 
The number of individuals served by these existing and emerging care models is likely on 
the rise. Diagnostic advances may mean that more individuals will be diagnosed in the earliest 
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stages of illness and have the capacity to participate in care planning and counseling. These 
advances are also expected to lead to a paradigm shift in social work and a movement from a 
focus on supporting the family through the illness process to engaging the person pursuing such 
testing, and their family, in care decisions. Social work roles will range from supporting the 
individual and their family through navigating care services, to counseling individuals coping 
with the diagnosis of a terminal illness, and framing these discussions within an understanding of 
emerging cognitive change. Most noteworthy is the additional counseling support that will be 
needed for clients and families to make decisions about participation in early diagnostic testing 
and understanding the ramifications of positive, negative, or inconclusive findings. This shift in 
focus coincides with a greater practice focus on understanding the experience of the person with 
cognitive impairment, in part by adopting a social model of care in which supporting the unique 
experience of the individual is a central theme. It also upholds the general movement towards a 
multidisciplinary approach to dementia care as the practice ideal, in which social workers 
collaborate with other health care professionals, including neurologists, psychiatrists, and nurse 
practitioners around assessment, diagnosis, treatment, counseling, and referral.  
Appropriate use criteria for AI (Johnson et al., 2013) identifies who may clinically 
benefit from AI, while exploring the psychosocial and health factors related to AI interest 
identifies those individuals that view a personal utility to be gained from AI, as well as those 
who may be opting out of access to AI testing. The inclusion of psychosocial factors in this 
dissertation additionally offers a more holistic view – from the social work perspective – of the 
person considering AI testing, identifying aspects of the individual that exist beyond their 
diagnostic status. Exploring the psychosocial, cognition and health-related factors that are 
associated with AI participation may inform social work-inclusive counseling protocols that 
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address the concerns of individuals who have varying levels of interest in such testing and who 
may need additional support in gaining access to such testing.  
Applying the above multidisciplinary approach to AI in a clinical practice setting may be 
happening soon. A multi-site study evaluating whether the clinical use of amyloid imaging 
improves health outcomes will begin in 2016, and aims to recruit over 18,000 Medicare patients 
via referrals from dementia specialist physicians (Zakaid, 2015). This will also be the first study 
to examine whether care coordination and counseling outcomes differ in relation to AI use and is 
ripe for a social work role in providing care management and support following results 
disclosure. Measured study outcomes include counseling for safety, medical and financial 
decision-making, advance directives, and community service referral (IDEAS Study, 2015).   
The implications of diagnostic testing are numerous for social work roles and social work 
research to provide evidence for best-practice approaches. It must be remembered that social 
work has had a long history of involvement in dementia care research and practice. Psychosocial 
interventions for dementia have been an ongoing focus within social work research. Work 
initially focused on the dementia caregiver (Pinquart & Sörensen, 2006) and extended our 
understanding of the importance of supporting the experience of the person with dementia 
(Cotrell & Schulz, 1993). Dementia-related biomarker research is creating a new frontier for 
practice and research. Ensuring the inclusion of a social work perspective is paramount, as it will 
advance our research and practice, but most importantly better serve individuals and families 
who are facing cognitive impairment.   
There is much potential for access and growth of amyloid imaging, where results are 
provided, and social work support needs to surround that process, informed by social work 
research. In addition to use in clinical settings, Centers for Medicare and Medicaid Services 
 13 
(CMS) currently covers scans completed in clinical trials where the impact on health outcomes 
or treatment options is of interest. This offers many opportunities for social work-inclusive 
research testing psychoeducational interventions that address outcomes such as emotional 
response to testing, health behavior change, adherence to service referrals, and safety measures, 
all informing best practices. As noted previously, a large CMS-funded study, with plans to 
recruit over 18,000 participants, will examine use of AI in clinical settings, and test its impact on 
outcomes, that include counseling for safety, medical and financial decision-making, advance 
directives, and community service referral, as well as related follow-through (IDEAS Study, 
2015). All would benefit from social workers embedded in physician practices that ensure these 
critical outcomes are met. In fact, whether CMS decides to approve reimbursement for AI in the 
clinical setting hinges on this study.  
Finally, there is much potential for the future expansion of AI to asymptomatic 
individuals. In fact, work is already underway to understand how people who are cognitively 
intact but approached for, or seeking, AI testing should be counseled (Harkins et al., 2015; 
Karlawish et al., 2013). Preventive clinical trials targeting asymptomatic individuals currently 
use screening protocols which include AI testing to determine eligibility for study participation. 
Individuals may receive AI results de facto, when deemed eligible (positive) or ineligible 
(negative). The counseling included in these trials is an important consideration. A more critical 
concern is gauging and supporting patient and family emotional response to testing and the 
receipt of results. While to date no research helps us understand the psychological effects of 
disclosure, there is a greater risk of suicide in early stages of AD, when insight is most preserved, 
rather than later stages (Lim, Rubin, Coats, & Morris, 2005). However, counseling protocols 
developed for AD-related genetic susceptibility testing point to the potential for providing 
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information on AD risk without creating psychological harm (Green et al., 2009). All points to 
need for social workers to be advocating for and pursuing roles in this area. 
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2.0  REVIEW OF THE LITERATURE 
This chapter provides a brief summary of Alzheimer’s disease (AD), including, prevalence, risk 
factors, and estimated costs to society, all noting the urgency for clinical and social work 
research aimed at improving the diagnostic and care management processes for Alzheimer’s 
disease. Next, current standards for diagnosis, treatment, and care management for cognitive 
impairment are summarized. This sets the stage for exploring how current social-work inclusive 
care protocols may be impacted by dementia detection advances, including a better 
understanding of the factors that impact patient uptake of such detection tools, in this case 
amyloid imaging. A brief summary of AI developments and their addition to diagnostic protocols 
are reviewed, setting the stage for conceptualizing and modeling AI research participation from a 
social work perspective using a biopsychosocial framework. The biopsychosocial domains under 
investigation and their potential for a significant relationship with AI interest and participation 
are reviewed in the context of research on preferences for cognitive assessment and screening, as 
well as AD susceptibility testing. This review provides a framework for characterizing 
individuals who express a preference for amyloid imaging and those who may be missing out on 
the potential benefits derived from AD diagnostic testing. Advances in diagnostic technology for 
AD are moving forward. An overarching aim of this dissertation was to both maintain and create 
space for social work research and practice in this arena. 
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2.1 PREVALENCE AND COSTS OF ALZHEIMER’S DISEASE 
Dementia is a progressive and fatal brain disease that affects almost 14% of individuals over age 
70 in the United States. Plassman et al. (2007). Approximately 5.3 million individuals in the U.S. 
have Alzheimer’s disease, the most common form of dementia (L. E. Hebert, Weuve, Scherr, & 
Evans, 2013), accounting for 60-80% of dementia cases (Thies & Bleiler, 2011). Dementia 
causes a general decline in cognitive abilities that interfere with daily life, including 
remembering new information, problem solving, thinking abstractly, and making sound 
judgments (Alzheimer's Association, 2015).  
Age is a key risk factor for AD. While approximately 11% of individuals over age 65 has 
AD, prevalence dramatically increases to almost 1 in 3 (32%) for those 85 years and older 
(Alzheimer's Association, 2015; L. E. Hebert et al., 2013). As life expectancies increase and the 
baby boom generation ages, the number of individuals with AD is expected to surge. By 2025 
approximately 7.1 million older adults (65 years and older) will be affected, a growth of 40 
percent from the 2015 estimate (Alzheimer's Association, 2015; L. E. Hebert et al., 2013). 
Mirroring an increase in prevalence, payments for health care, long-term care, and hospice for 
individuals with dementia are projected to grow from $226 billion in 2015 to more than $1 
trillion in 2050 (Alzheimer's Association, 2015). Medicare and Medicaid shoulder the brunt of 
these costs, at a combined 68% (Alzheimer's Association, 2015).  
Improved diagnostic and treatment protocols might positively impact the lived experience 
of AD for both patients and caregivers. Unpaid caregivers, predominantly family members, 
experience significant burden, clocking in an estimated 17.9 billion hours of unpaid care valued 
at more than $217 billion in 2014 (Alzheimer's Association, 2015). They report high levels of 
stress and depression, as their care roles adversely impact health, employment, and financial 
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status (Alzheimer's Association, 2015). Though less studied, and in addition to the progressive 
loss of cognitive and functional abilities, individuals diagnosed with dementia clearly experience 
negative outcomes from the disease, such as anxiety, depression, and psychosis (Lyketsos et al., 
2002; Steinberg et al., 2003).  Individuals with dementia also report experiencing a loss of 
autonomy and security (Steeman, De Casterlé, Godderis, & Grypdonck, 2006). Creating a 
diagnostic process that is more responsive to patient conditions and needs may improve patient 
and family outcomes following diagnosis. The chronic care model (Bodenheimer, Wagner, & 
Grumbach, 2002), and efforts to apply the patient-centered medical home model to dementia 
care (Callahan et al., 2011), have been proposed as viable approaches to address both the 
medical, emotional and social needs of the patient-family dyad seeking diagnosis and care, as 
well as reduce care costs (Callahan et al., 2006). 
2.2 DIAGNOSIS AND TREATMENT OF ALZHEIMER’S DISEASE 
New guidelines of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for 
diagnosing cognitive impairment, including Alzheimer’s disease, have renamed the categories 
for cognitive impairment to major and mild neurocognitive disorder (NCD) (American 
Psychiatric Association, 2013). The DSM-5 rubric for a diagnosis of major neurocognitive 
disorder describes symptoms that include a significant decline in memory or another cognitive 
ability (e.g. language, learning, or executive function) that interfere with independently carrying 
out one or more activities of daily living. Mild neurocognitive disorder is defined by a decline in 
cognitive ability that does not obstruct completion of daily activities, though it may mean that a 
certain activity requires more mental attention. Alzheimer’s disease, considered an etiologic 
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subtype of both major and mild NCD, then follows as a diagnosis. AD would be differentiated 
from other types of dementias based on disease course and cognitive presentation, behavioral 
and/or psychological symptoms, known risk factors, and findings from brain imaging (American 
Psychiatric Association, 2013).  
A diagnostic work-up for dementia is most often completed by a primary care provider 
and ideally includes a family and medical history, psychiatric history and an assessment of 
cognitive and behavioral changes (Alzheimer's Association, 2015). Patients might also complete 
neuropsychological tests and a neurologic examination. Brain imaging may be ordered to rule 
out other brain abnormalities such as a tumor or stroke. A review of studies examining diagnostic 
accuracy for AD, comparing diagnosis to autopsy findings, reported good sensitivities ranging 
from 65-95%  (Dubois et al., 2007).  
Mild cognitive impairment (MCI) now falls under the domain of mild neurocognitive 
disorder within the DSM-V (American Psychiatric Association, 2013) and captures those 
individuals who are experiencing declines in memory that are noticeable but not presentations of 
AD. Specifically, an MCI diagnosis means that an individual’s ability to carry out daily activities 
is not wholly impeded by memory changes, as in the case of AD.  
Estimates of conversion from MCI to AD range from 11% to 64%, after 2 years 
(Ganguli, Dodge, Shen, & DeKosky, 2004; Geslani, Tierney, Herrmann, & Szalai, 2005). 
Variation in sampling method drives the large range of conversion rates; university-based 
memory clinic samples (Geslani et al., 2005) have much higher rates of conversion than 
population-based samples (Ganguli et al., 2004). Population-based studies may include a 
potentially less rigorous assessment process that is most adaptable for administration in a range 
of community-based settings, but is unfortunately susceptible to information bias. However, 
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these studies benefit from the inclusion of a more sociodemographically diverse of individuals, 
applying a less rigorous inclusion criteria, for improved sampling. Study samples derived from 
university-based memory clinics, including the sample for this dissertation, may be impacted by 
selection bias; participants have self-selected to participate in assessment and also meet specific 
criteria for participation, a benefit for inclusion-specific clinical trials. Yet their strength is data 
collection using a highly standardized, comprehensive assessment (Kukull & Ganguli, 2012). 
Currently there is no single test that definitively reports whether an individual has or will 
develop AD, although the continued development of biomarker testing, with amyloid imaging 
being a key leader, moves science closer to an ideal and more accurate diagnostic protocol.  
Unfortunately, no treatment exists that can delay or prevent AD, although many 
medication studies are underway that specifically target beta-amyloid accumulation and amyloid 
imaging is often included in the study protocol. In fact, amyloid imaging has been a significant 
catalyst for AD drug development, and much work has been directed toward determining the 
amyloid status of individuals diagnosed with AD, as well as individuals with MCI, or in another 
prodromal, or preclinical stage of dementia. Allowing for identification of amyloid status allows 
for an examination of whether changes in amyloid deposition occur over the course of the drug 
trial (Johnson et al., 2013).  
Current medications may temporarily improve symptoms, although none alter the 
underlying course of the illness. Currently the best approach to care involves ongoing, active 
management of AD that includes the use of anti-dementia medications and management of co-
occurring illnesses, but importantly also includes effective care coordination across health and 
social service needs (Vickrey et al., 2006). It is noteworthy that social work professionals are 
often leads or key participants in the care team, providing ongoing support for individuals with 
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AD and their families, either via home or long-term care coordination, or via psychosocial 
interventions (Parker & Penhale, 1998). 
2.2.1 Amyloid imaging for the diagnosis and treatment of Alzheimer’s disease 
The amyloid hypothesis is a widely accepted theory that explains how the degeneration of brain 
cells occurs in AD (Hardy & Selkoe, 2002) and has accordingly driven neuroimaging research to 
detect amyloid in the brain. Research is even progressing to studies examining the clinical 
effectiveness of amyloid imaging. An upcoming multi-site study funded by the Centers for 
Medicare and Medicaid (CMS) plans to examine patient outcomes related to completion of AI 
for dementia diagnosis and is intended to inform future CMS reimbursement protocols for AI 
(IDEAS Study, 2015).  The following section describes the amyloid hypothesis and the history of 
research on AI. 
To summarize, the amyloid hypothesis reasons that problems with the production, build 
up or disposal of beta-amyloid (a protein fragment in the brain) results in AD pathology. Deemed 
chemically “stickier” than other protein fragments, beta-amyloid accumulation eventually results 
in amyloid plaques. This accumulation is believed to interrupt communication between brain 
cells and triggers immune cells to cause both overall inflammation and the build-up of disabled 
cells, all ultimately resulting in cell death and brain atrophy. Based on the amyloid hypothesis, 
the investigation of technologies to image amyloid in the brain has flourished (Klunk et al., 
2004).  
Considered a biomarker test, AI uses positron emission tomography (PET) to detect 
amyloid plaques in the brain using a radioactive compound that binds to amyloid-beta, making it 
visible in PET imaging. Pittsburgh Compound B, or PiB, is one of several compounds under 
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investigation for imaging amyloid-beta (Klunk et al., 2004) and is widely used in clinical trials 
and longitudinal studies of AD. Completing AI can help clarify whether an individual’s 
neurocognitive symptomatology is originating from an AD source and even detect amyloid in the 
brains of individuals who are cognitively intact (Aizenstein et al., 2008). A review of PiB 
retention studies reports that over 50% of individuals diagnosed with MCI are positive for 
amyloid deposition while 25% of individuals who are cognitively normal are amyloid positive 
(Lingler & Klunk, 2013).  
PiB, while not yet approved for clinical marketing by the FDA, has been widely used in 
studies investigating diagnosis and treatment protocols for AD (Mueller et al., 2005; Rinne et al., 
2010). Developed by University of Pittsburgh researchers, an initial study comparing individuals 
diagnosed with AD to healthy controls showed significant retention of PiB in individuals with 
AD versus older adults with no cognitive impairment (Klunk et al., 2004). PiB has also been 
used to identify amyloid deposition in the brains of individuals with no cognitive impairment, 
indicating that AI may be used to detect a preclinical stage of AD (Mintun et al., 2006). Another 
study found that greater binding of PiB to cortical areas of the brain predicted progression from 
normal cognition to symptomatic AD (Morris, Roe, Grant, & et al., 2009). 
Three other radiotracers have been developed for use in detecting beta-amyloid in the 
brain (Barthel et al., 2011; Clark et al., 2011; Vandenberghe et al., 2010). The compounds differ 
in length of stability; radiotracers with a longer half-life span allows for greater flexibility of its 
use in research and clinical settings. One radiotracer for detecting amyloid-beta, florbetapir, was 
approved for marketing to clinical settings by the U.S. Food and Drug Administration (FDA) just 
last year, in April 2012 (U.S. Food and Drug Administration, 2012). Florbetapir is indicated for 
use in individuals with cognitive impairment who are undergoing an evaluation for AD or 
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another type of cognitive decline. Indications and limitations of use specifically stipulate that 
florbetapir is not intended to “establish a diagnosis of AD” and should be used as an “adjunct to 
other evaluations” (Lilly, 2013). Comparisons of scan readings for PiB and florbetapir show a 
strong association and provide comparable findings (Landau et al., 2013; Wolk et al., 2012).  
The estimated cost of a florbetapir scan, including a radiologist’s read of the scan and the 
use of a PET scanner, is approximately $3,000. Hearings regarding reimbursement by CMS were 
held in January 2013, with no plan for reimbursement resulting (Centers for Medicare and 
Medicaid Services, 2013). In hearings, debate persisted over whether lack of effective AD 
treatments make florbetapir impractical with respect to care outcomes or whether the potential 
for care management following early diagnosis can result in cost savings and better care 
outcomes (Centers for Medicare and Medicaid Services, 2013). The IDEAS study, which will be 
initiating recruitment in 2016, will determine whether AI leads to an improved diagnostic 
process, more appropriate treatment and care recommendations, and better patient health 
outcomes (i.e. reduced emergency department admissions and hospitalizations) (IDEAS Study, 
2015). 
This first substantial clinical study was supported by years of research exploring the 
efficacy and use of PiB. Previous research includes cross-sectional and longitudinal studies of 
PiB, all with the aim of building a research base to document how PiB binds to amyloid in 
varying parts of the brain and under what symptomatic conditions amyloid might be visible. 
Patient interest in amyloid PET research studies conducted at the University of Pittsburgh 
ADRC, a primary home of AI research, comprised the outcome variable of this dissertation and 
allowed for a panoramic snapshot of early adopters of AI and their related ADRC 
biopsychosocial assessment data.  
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2.3 MODELING AMYLOID IMAGING PARTICIPATION 
The following sections describe how this dissertation conceptualizes amyloid imaging interest, 
including how levels of interest are derived and what they potentially signify. Given this is the 
first known study that quantitatively explores interest in amyloid imaging, two bodies of research 
are summarized that explore the drivers of interest in AD genetic testing and cognitive screening 
and assessment. The biopsychosocial model is presented as a framework for understanding 
interactions across individual, social, and medical variables and with AI interest. All provide a 
useful backdrop for hypothesizing what characteristics are associated with AI interest. 
2.3.1 Conceptualizing interest in amyloid imaging 
Previous studies have explored interest in neuroimaging participation for AD from the patient 
perspective. Of research looking at patient preferences for neuroimaging, reported interest was 
lower in a sample of primary care patients (62.7%; Magin et al., 2015) than among participants 
in a university-based memory clinic (78%; Lingler, Rubin, & Saxton, 2010), although in each 
environment, the majority of respondents do express interest. Lingler and colleagues (2010) 
further found that one third of the sample indicated a different preference regarding brain 
imaging study participation one year later, and overall high interest continued. Of note, this work 
sets the stage for the conceptualization of AI interest in the current study, as the same data source 
for the dependent variable -- interest in neuroimaging research participation -- will be used.      
When examining interest in dementia diagnostic status, irrespective of testing protocol, 
high percentages of individuals express a preference for knowing their dementia diagnostic 
status, according to a systematic review pooling samples of studies of individuals with no 
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cognitive impairment (90.7%) and individuals seeking assessment at a memory clinic (84.8%) 
(van den Dungen et al., 2014). These findings are somewhat supported by an international phone 
survey gauging public opinion about dementia testing. Among Americans sampled, 89% would 
go to a doctor if they were “exhibiting confusion and memory loss…to determine if the cause 
was Alzheimer’s disease” (Blendon et al., 2012, p. 4). However, far fewer (29%) would be “very 
likely to get a diagnostic test if, in the future, one became available that would tell people before 
they had symptoms whether they will get Alzheimer’s disease” (Blendon et al., 2012, p. 4). 
These differences are possibly due to differences in sample composition and the specific focus 
on preclinical state used in the public opinion poll. 
Family caregivers also generally support diagnostic disclosure to the patient; although 
when family members do express concern about disclosure, worries regarding the emotional 
response of the patient are primary (Holroyd, Turnbull, & Wolf, 2002). Ethical guidelines for 
dementia diagnostic disclosure promote a consideration of patient wishes regarding disclosure 
and information sharing (Fisk, Beattie, Donnelly, Byszewski, & Molnar, 2007). While overall 
disclosure regarding diagnostic status is valued, preferences regarding testing in asymptomatic 
stages are likely to vary, for a range of reasons. The following section presents a framework for 
exploring factors related to AI interest. 
As outlined earlier, the following categories capture interest levels in AI: 1) AI 
participants (Participators); 2) individuals who decline AI participation but indicate initial 
interest in imaging studies (Avoiders); and 3) individuals who indicate they do not want to be 
contacted regarding imaging studies, and in fact never agree in an AI study (Refusers). Refusers, 
Avoiders and Participators share the experience of being asked whether they would like to be 
contacted regarding participation in a neuroimaging study. Those who agree to contact (Avoiders 
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and Participators) and then delineated by whether they agree participation in an AI study. From 
these decision points, varying AI interest is derived and grouped into three categories.  
Refusers are considered to have the strongest disinclination to participate in amyloid 
studies. This group may not perceive a value to be derived from participation in AI research, and 
social altruism may not be enough of a pull. They also have a shared experience of never 
receiving further information regarding the purpose and protocol involved in AI study 
participation, and may be more likely to have less knowledge of AI than Avoiders or 
Participators. Avoiders, who are open to discussion of AI participation with a study recruitment 
coordinator and then decline participation, experience a potentially more informed decision 
process. Their initial expression of interest likely means greater exposure to information about 
amyloid imaging and they decline following this knowledge gain. Avoiders and Participators 
share the experience of learning about the AI process and the rationale for such research, but 
diverge in their final decision about AI participation. The Participators group captures those with 
an active interest in AI – individuals who have agreed to both contact and have carried out 
participation in one or more AI studies. 
While none of the Participators receive the results of AI imaging, other work has 
supported that there is an interest in receiving research results among university-based memory 
clinic participants (Gooblar et al., 2015), implying that hope may exist among participants that 
future disclosure is possible. This is supported by the University of Pittsburgh ADRC amyloid 
imaging study recruitment coordinator, who has noted that the majority of participants in AI 
studies would like to receive imaging results. Individuals diagnosed with MCI or normal with 
subjective complaints report interest in results, as do AD caregivers whose loved one has 
participated in AI imaging. Participants may also be motivated by the availability of additional 
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imaging that is apart from amyloid PET, is free of charge, and may provide new information 
regarding their condition. Maintaining a stronger connection to ADRC clinicians through study 
participation may also be valued by this group, with the hope that such a connection may lead to 
a deeper understanding of diagnosis or sense of closeness to the forefront of research, where 
access to the most advanced treatment options is more possible. Of note, while many studies do 
offer compensation of up to several hundred dollars and transportation as needed, anecdotally, 
few individuals describe this as a prime motivating factor. 
2.3.2 Frameworks for exploring amyloid imaging interest and participation 
In addition to modeling AI interest based on a biopsychosocial framework, participation in 
genetic testing for AD and cognitive screening or assessment serve as a framework for 
understanding the associations between demographics and family history, as well as cognitive 
status, health, and mental health status. In particular, these frameworks are used to generate 
hypotheses regarding the variable associations that are presented in the following sections.  
 
Biopsychosocial model for amyloid imaging interest and participation 
The medical model for dementia allowed for a movement from dementia viewed as a 
normal part of aging, to dementia conceptualized as an individualized disease process caused by 
progressive deterioration of the brain, that could be medically managed and treated (Lyman, 
1989). It also, however, reduced social work and other allied health professionals to care 
assistants, under the direction of doctors and in supplemental or secondary roles (Kaplan & 
Andersen, 2013). It additionally considered the patient to be a passive actor in the care decision-
making discussions (Kaplan & Andersen, 2013). Viewing dementia in a medicalized frame also 
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reduced the individual with dementia to their illness and symptom report, omitting the many 
dynamic psychosocial aspects of the individual that impact the illness experience and trajectory 
experience (Lyman, 1989; Spector & Orrell, 2010). 
While written about to advocate a transformative model for medicine, the 
biopsychosocial model has long been embraced by social work as a tool for assessment and 
intervention with older adults (Greene, 2011; McInnis-Dittrich, 2005). The biopsychosocial 
model developed in response to a recognized need to move from independent and separate 
assessment of medical and psychosocial determinants surrounding assessment, diagnosis, and 
treatment to a merged model of care (Engel, 1977). It is derived from a general systems theory 
approach which considers varying factors surrounding an individual to be collectively and 
intrinsically linked. It also provides a connection between care delivery and the study of disease 
(Von Bertalanffy, 1950; Von Bertalanffy & Sutherland, 1974). Engel proposed the 
biopsychosocial model as a way to take into account varying patient-related and social-system 
factors as a part of care (Engel, 1977). Most importantly, patient report is given equal value to 
illness presentation (Engel, 1977).  
It has been specifically applied to social work practice in dementia care (Kaplan & 
Andersen, 2013; Keady et al., 2013). For example, Spector and Orrell (2010) modeled a 
framework applying the biopsychosocial model to dementia care. They identified biological and 
psychosocial factors, both fixed and tractable, as well as related biological and psychosocial 
interventions, that impact dementia progression. Differentiating between fixed and tractable 
factors acknowledges those tractable biological and psychosocial factors that are amenable to 
change and may be impacted and improved. Factors may be considered risk factors or protective 
factors for dementia. Of note, dementia is modeled as a disease trajectory and progresses from 
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normal aging, through early organic change (without symptoms), through MCI and dementia 
diagnosis, to end-of-life care and death.  
Applying the biopsychosocial model to this dissertation work allows for an exploratory 
examination of the associations between interest in AI and biological or medically determined 
variables (cognition, physical, and mental health status) and psychosocial variables 
(demographics, dementia family history, and informal care support; see Figure 1 for a pictorial 
representation). It additionally allows for exploration of interactions across independent variable 
groups, in relation to AI interest. To further delineate the potential relationships across these 
variables, a summary of the literature exploring interest in AD genetic testing, memory 
screening, and cognitive assessment literature is described in detail below. 
 
 
 
Figure 1. Conceptual framework using the biopsychosocial model to depict interest in amyloid imaging 
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Genetic testing for Alzheimer’s disease  
Studies examining participation in genetic predictive and susceptibility testing for AD 
serve as one basis for exploring what factors may relate to participation in AI. Roberts et al. 
(2013) outline the key differences between susceptibility testing for AD and amyloid imaging, 
noting fixed results for genetic testing and potentially changing findings for AI, as amyloid status 
may change from negative to positive. A second important difference is that evidence for AI 
points to a more definitive determination of hallmark pathology, with a risk of clinical AD 
developing in the next 10-15 years for asymptomatic individuals. However, genetic testing 
shares many similarities with AI. Both allow individuals to know whether a condition exists that 
increases the likelihood of developing or having AD. Overall there are likely similarities in those 
who would express interest in completing each kind of diagnostic procedure, making the AD-
related genetic testing literature an appropriate backdrop for the hypotheses generated in this 
study.    
A range of studies have explored how genetic testing for AD risk is viewed, as well as 
what factors relate to participation in such testing. These studies employ a variety of research 
designs, ranging from hypothetical descriptions of genetic testing procedures (Roberts, 2000), to 
randomized controlled trials examining the feasibility and acceptance of genetic susceptibility 
testing (Green et al., 2009). Most samples include only individuals with first-degree relatives 
with AD, as their predisposition for AD may be all the more salient.  
Across study designs, a high interest in testing is evident. Neumann et al. (2001) 
conducted phone interviews with a random sample of adults (N=314) and found that more than 
three-quarters would complete a predictive test for AD; however interest dropped to 49% for 
partially predictive testing. A study presenting differing hypothetical scenarios (e.g. varying 
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degrees of test accuracy, level of risk associated with a positive finding, and treatment 
availability) to adults with first degree family members with AD (N=203) reported that the 
majority of participants expressed interest in genetic testing, even when testing accuracy was 
limited (Roberts, 2000). Recruitment into a randomized controlled trial examining the delivery of 
AD genetic susceptibility testing results greatly exceeded expectations, warranting concerns that 
the current genetic counseling services available may not be sufficient to meet the anticipated 
demand for such testing (Roberts et al., 2004).  
While limited treatment options inhibit the expansion of such testing and research points 
to fewer numbers of individuals expressing interest in genetic testing participation who actually 
follow through with participation, this high initial interest is worthy of consideration. The 
following sections will explore what psychosocial factors differentiate between those who 
express willingness to pursue testing and those who do not. Additionally, the drivers of initial 
interest in testing, compared to those factors associated with testing completion, will help 
establish a framework for exploring whether differences exist in the factors that define AI 
interest and participation groups.   
 
Participation in cognitive screening and assessment 
In addition to the literature on participation in AD-related genetic testing, a body of 
research has also explored factors associated with willingness to participate in initial memory 
screening or cognitive assessment. These studies provide a needed backdrop, as they offer a 
greater depth of exploration and theory testing, particularly in regards to the psychological 
factors related to testing interest. Another key aspect of this research is the addition of studies 
that explore factors associated with the decision to actually undergo a memory assessment, again 
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allowing for a review of factors that distinguish between who expresses intent to undergo 
memory testing and who actually completes such testing.  
Eight sets of studies have explored this area, all including older adults with no known 
diagnosis of memory impairment. As in genetic studies, hypothetical scenarios were employed to 
explore whether there are differences in who expresses intent to undergo assessment and who 
declines (e.g. Boustani, Watson, Fultz, Perkins, & Druckenbrod, 2003; Boustani et al., 2011; 
Dale, Hemmerich, Hill, Hougham, & Sachs, 2008; Werner, 2003). Two studies incorporated 
scenarios in which respondents were asked to imagine different conditions under which they 
would express assessment intent, including concerns about memory changes (Dale et al., 2008; 
Werner & Heinik, 2004) or given a family history of AD (Werner, 2003). Two studies examined 
differences between those who completed memory screening and those who went on to complete 
diagnostic testing post screening (Boustani et al., 2006; Demirovic et al., 2003), while one study 
explored the reasons individuals who complete screening would pursue diagnostic testing 
(Williams, Tappen, Rosselli, Keane, & Newlin, 2010) and one explored factors impacting the 
decision to seek assessment among individuals with subjective memory complaints (Hurt, Burns, 
Brown, & Barrowclough, 2012).  
Intention to participate in memory screening ranged across studies, from a low of 49% 
among older adults residing in independent living communities who were asked about interest in 
routine memory screening (N=500; Boustani et al., 2003), to high interest (97% reporting 
definitely or probably yes) in MCI screening when, hypothetically, a family member indicates 
concerns (N=199; Dale et al., 2008). For those interested in MCI screening, knowing as early as 
possible whether memory symptoms were an indication of AD was the most robust predictor of 
intent (Dale et al., 2008). Actual participation in cognitive assessment is substantially lower, 
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however. Among those who elected to complete a memory screening and, based on screening 
outcome, were referred for a diagnostic cognitive evaluation, less than half decided to pursue an 
evaluation (Boustani et al., 2006; Demirovic et al., 2003). 
Compared to genetic testing studies, more variation in interest and completion of memory 
assessment is evident. Reasons for this variation seem to hinge on differences in sample 
composition and measurement, and will be explored in the following sections. Additionally, 
factors associated with intent to pursue such testing, in comparison to actual testing completion, 
seem to vary, and this difference is examined below. 
 
Factors associated with interest and participation in AD genetic testing and cognitive 
assessment 
Demographics. Age, race, gender, and education level may play a role in who chooses to 
participate in AI. The following section describes the varying relationships reported for genetic 
testing and cognitive screening intent and participation. Based on these findings, hypotheses are 
derived for AI interest and for each demographic.  
Age. Overall, younger age groups seem to express more interest in genetic testing and 
assessment for AD. Older adult primary care patients with no dementia diagnosis (N=554) were 
more likely to express willingness to complete a memory screening if they fell in a younger age 
group (Fowler et al., 2012). In a sample of adults from a geriatric outpatient clinic (N=199), 
younger individuals (< 65 years) were more likely to express intentions to participate in MCI 
screening if memory symptoms were (hypothetically) evident (Dale et al., 2008).  
The same finding held in relation to intent to participate versus actual participation in a 
cognitive evaluation. Werner (2003) reported that interest in cognitive assessment was more 
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evident among younger individuals with a first-degree family history of AD. The same was true 
for participation in a diagnostic cognitive assessment among a sample of older primary care 
patients (N=434; Boustani et al., 2006) and a community-based, multi-ethnic sample of older 
adults (N=310; Demirovic et al., 2003), when memory screening findings indicated need for 
follow-up. Among individuals with a family history of AD (N=196) who were approached for 
participation in a randomized clinical trial testing an AD genetic risk assessment counseling 
intervention, those less than 60 years old were more likely to participate in the trial (Roberts et 
al., 2004). 
Just two studies reported age was non-significant in modeling; one exploring willingness 
of individuals with a family history of AD to participate in genetic testing (Roberts, 2000) and 
another exploring intent of first degree relatives to participate in a cognitive assessment (Werner 
& Heinik, 2004). A potential interaction between family history and age may alter findings and 
both variables will be included in this dissertation to further tease out a relationship.  
Race. The relationship between race and preferences for testing are mixed. African 
Americans are reported to be significantly more likely to express willingness to participate in 
MCI screening (Dale, Hougham, Hill, & Sachs, 2006) and to seek a cognitive assessment 
(Demirovic et al., 2003) than whites. Another study reported that younger African Americans 
were significantly more likely to complete a cognitive assessment than younger whites (less than 
80 years of age) or older African Americans (aged 80 or older) (Boustani et al., 2006). African 
Americans are reported to be less likely to be interested in pursuing AD-related genetic testing 
than whites and report fewer reasons for participation in such testing (Hipps, Roberts, Farrer, & 
Green, 2003). No studies were found that examined AD genetic susceptibility testing in relation 
to other racial or ethnic groups. In fact, in some studies race was not explored as a factor 
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associated with interest in genetic testing due to the limited racial variability in the sample 
(Roberts, 2000; Roberts et al., 2004). An awareness of greater dementia prevalence among 
African Americans may be stimulating this interest in assessment and may be partially driving 
the overall findings in these studies (Gurland et al., 1999). A review of qualitative studies 
exploring the experience of diagnostic disclosure reported greater evidence of stigma related to 
dementia among minority ethnic groups than whites (Bunn et al., 2012), indicating the potential 
for lessened interest in AI. The present study will further explore this relationship, with a sample 
comprised of African American (7.5%) and white (92.5%) participants.  
Sex. Less is known regarding the relationship between gender and AD testing interest. 
Just one study found an association between AD genetic testing interest and gender, in which 
men were significantly more likely to express interest in testing participation than women 
(Roberts, 2000). Additionally, Boustani et al. (2003) reported that older adult males living in a 
continuing care retirement community were more likely than females to express interest in 
memory screening. Other studies have reported no significant associations with gender (Dale et 
al., 2008; Demirovic et al., 2003; Green, Clarke, Thompson, Woodard, & Letz, 1997). A larger 
proportion of women do have AD; however this trend is largely explained by the longer life 
expectancy of women (Hebert, Scherr, McCann, Beckett, & Evans, 2001). Given this greater 
prevalence, it may be that women perceive greater harms from testing or screening (Boustani et 
al., 2003), although this seems to be a deficient rationale for any trend and it could be that a non-
association is present. 
Education level. Green et al. (1997) reported an association between lower education 
level and interest in a hypothetical, highly accurate, predictive genetic test for AD. Similarly, 
Dale et al. (2008) reported that individuals with a lower level of education were more likely to 
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express interest in MCI screening if a family member suggested memory problems were present, 
possibly indicating less comfort with their ability to self-identify memory changes. However, no 
differences in education level were reported in studies examining who goes on to participate in 
diagnostic assessment (Boustani et al., 2006; Demirovic et al., 2003). Furthermore, a study 
examining participation in genetic risk assessment counseling, as part of a randomized clinical 
trial, found those with at least a college education were more interested in participation. Overall, 
findings are mixed, possibly due to varied samples and the range of assessment involvement 
participants are questioned about. 
While drawing firm conclusions regarding demographic factors associated with testing 
participation is not possible, they provide a starting point for the further investigation of these 
factors. The following hypotheses are derived based on these findings for the full sample and 
individuals with dementia: Younger age will be significantly related to interest in, as well as 
participation in, AI. No significant relationships regarding gender, race, or education level are 
anticipated.  
 
Neurocognitive status. Self-perception of cognitive impairment has been the primary 
way that the relationship between cognition and interest in dementia testing has been explored, 
with varied findings reported. In an Israeli study sampling individuals with a first degree relative 
with dementia (N=93), having subjective memory complaints was predictive of interest in 
seeking a cognitive assessment (Werner & Heinik, 2004). However, among studies examining 
participation interest in memory screening, individuals who actually believed they had a memory 
problem were less likely to report interest in seeing a doctor for MCI screening if an instance of 
memory change was occurring (Dale et al., 2008). Another study found that self-report of a 
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memory problem was not indicative of interest in regular memory screening (Boustani et al., 
2003). 
Among studies employing measures of cognitive status, findings also differed. In one 
study older adults with worse performance on screening instruments had a higher probability of 
following through with the completion of a dementia assessment than those with better screening 
scores who were also referred for diagnostic assessment (Boustani et al., 2006). Another study 
using hypothetical scenarios to explore participant willingness to participate in AD research 
found that overall interest in AD-related study participation did not differ between individuals 
with and without cognitive impairment (Kim, Cox, & Caine, 2002). However, among individuals 
with mild to moderate AD (N=34), greater decisional impairment was associated with less 
interest in research participation.  
Younger age at onset of cognitive symptoms may relate to whether an individual 
completes AI. Misdiagnosis of early onset AD is common and accuracy in diagnosis is critical to 
disease management as well as patient and family care planning (Werner, Stein-Shvachman, & 
Korczyn, 2009). For individuals with a young-onset dementia disorder, increasing diagnostic 
certainty regarding the cognitive disorder may be all the more critical for access to care and 
disability services. Although not in place when the individuals in the current study sample were 
approached about AI interest and participation, criteria for the clinical use of amyloid imaging 
include individuals presenting with early-onset AD among those who may benefit from its use 
(Johnson et al., 2013). Each of these aspects may make AI more attractive for younger 
individuals with dementia. 
Receiving information about cognitive status, particularly the news that cognition is 
declining and mild cognitive impairment or dementia has been detected, may impact patient 
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interest and participation in neuroimaging. One study in which semi-structured interviews were 
completed with individuals diagnosed with MCI found that many participants felt that imaging 
was onerous to complete and did not seem appropriate in relation to their symptoms (Dean, 
Jenkinson, Wilcock, & Walker, 2014). Perceptions and preferences for neuroimaging are likely 
affected by the information exchange and communication dynamics that occur throughout the 
assessment and diagnostic process among patient, family members, and clinicians. A social work 
study completing qualitative interviews with individuals recently diagnosed with cognitive 
impairment and their families found an expressed interest in receiving more information about 
their diagnostic status, with one participant expressing, “knowing everything was better than not 
knowing” (Abley et al., 2013). This may be equated with an interest dementia study participation 
that is deemed to improve patient and family understanding of the patient’s diagnostic status. 
How individuals view the seriousness of their subjective memory complaints may explain 
the variation in findings. Among those comprising the current study sample and who are 
presenting to the Alzheimer Disease Research Center with memory complaints, as well as 
actively pursuing evaluation, there is certainly a greater worry regarding memory symptoms. 
Therefore, when considering the relationship between cognitive status and AI participation, we 
surmise that an inverse association may be present. Individuals with less impairment (e.g. MCI 
or no dementia but possibly subjective memory complaints) may express a greater interest in AI, 
as there may be more interest in gaining additional insight about their individual potential for a 
disease process. Less impairment also indicates greater ability to discern the meaning of 
participation in such a process, allowing better understanding and therefore acceptance of testing. 
It is important to note that for individuals with a diagnosis of dementia, family members may 
play a greater role in determining participation in AI.   
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To conclude, given the range of findings in relation to cognitive status and taking into 
account the unique nature of AI, we hypothesize that the following factors will be significantly 
associated with AI interest and participation: 1) having a diagnosis of no cognitive impairment, 
or mild cognitive impairment, rather than dementia; 2) better performance on cognitive testing, 
in this case the Mini Mental State Exam; 3) younger age at onset of cognitive symptoms; and 4) 
change in diagnostic status. Among individuals with dementia, we hypothesize that 1) better 
performance on cognitive testing; and 2) younger age at onset of cognitive symptoms will be 
significantly associated with AI interest and participation. 
 
Family history. Given that a higher risk of AD is associated with family history of 
dementia (Green et al., 2002), several studies have limited sample composition to individuals 
who have an immediate family member diagnosed with AD (Roberts, 2000; Roberts et al., 
2004). These individuals are considered to have a high interest in genetic testing for AD, which 
is supported by study findings (Roberts, 2000). Understanding how individuals perceive the 
importance of family history is especially salient as it may also play a role in determining who is 
referred for AI.  
Three genetic testing studies have further explored the relationship between family 
history and genetic testing interest by including individuals with and without a family history and 
using varied samples, including: a community-based convenience sample (Green et al., 1997); a 
general population sample via random-digit dialing (Neumann et al., 2001); and a matched 
comparison group sample of individuals with no family history compared to individuals with a 
living parent diagnosed with AD (Cutler & Hodgson, 2003). Results from these studies were 
somewhat mixed; there was a trend toward more interest among individuals with family history 
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of AD, although the difference was significant in just one study (Green et al., 1997). Individuals 
asked about interest in completing a hypothetical, highly accurate predictive test for AD were 
significantly more likely to express interest if they had an AD family history (Green et al., 1997). 
Of studies with non-significant findings, Neumann et al. (2001) found that those with a family 
history reported greater interest in predictive testing than those without a family history (90% 
versus 77%), while interest in partially predictive testing was more similar (49% versus 44%). 
One limitation was that the definition of family history varied, in one case extending beyond 
immediate family members to grandparents (Neumann et al., 2001), potentially skewing risk 
perception. Cutler and Hodgson (2003) also found that adult children asked about participating in 
100% accurate, predictive testing had a slightly greater interest (68%) than individuals with no 
family history (62%), but again the difference was non-significant.  
Across studies examining interest in memory screening or uptake of cognitive 
assessment, findings are also somewhat mixed. One study’s sample included only individuals 
with a first degree relative with AD, who reported moderate interest (42%) in cognitive 
assessment within the next one to 5 years (Werner & Heinik, 2004). Another found that older 
adults expressed more interest in cognitive evaluation when presented with a scenario in which 
they had a relative with AD (Werner, 2003). A third study supported these findings, based on 
semi-structured interviews completed with a multi-ethnic sample of older adults who were more 
receptive to both memory screening and cognitive evaluation when a family history of AD was 
evident (Williams et al., 2010).  
Family caregivers of individuals with dementia had a lower acceptance of dementia 
screening than non-caregivers, and although information regarding family relationship was not 
available, caregivers in the sample were significantly more likely to believe they were at risk for 
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developing AD than non-caregivers (Boustani et al., 2011). Additionally, caregivers who were 
supporting family members with dementia-related behaviors reported lower intention to 
complete a cognitive evaluation (Werner & Heinik, 2004). It may be that personal experience 
caring for a loved one with dementia may alter views about the utility of testing and enhances 
perceptions of AD as a threat with significant repercussions.    
Given the above findings and the potential for differing outcomes based on type of family 
history, the following hypothesis is derived for the full sample and the subsample of individuals 
with dementia: having family history of AD will be significantly associated with AI interest and 
participation. 
 
Health status. Other health conditions may take precedence over AI participation, 
although few studies have examined how comorbid health issues impact interest in cognitive 
testing. Having two or more medical comorbidities was significantly related to greater interest in 
routine memory screening among older adults residing in a retirement community (Boustani et 
al., 2003).  However, a history of stroke was not associated with participation in cognitive 
assessment following memory screening referral (Demirovic et al., 2003). Given the strong 
association between cardiovascular health and the higher risk of AD (Alzheimer's Association, 
2012), it seems important to note whether the presence of health conditions, such as 
cardiovascular disease, diabetes, high cholesterol, and hypertension, all of which negatively 
impact cardiovascular health, lead individuals to pursue testing for AD. Based on the above 
findings and the association between cardiovascular health and AD, the following hypothesis 
will be tested: presence of health comorbidity will be significantly associated with AI interest 
and participation for both the full sample and subsample of individuals with dementia.   
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Mental Health Status. Studies examining the relationship between mental health and AD 
testing participation have primarily focused on documenting whether testing engagement leads to 
psychological distress, particularly following diagnostic disclosure. In fact, studies have 
documented that after a disclosure of a dementia diagnosis (Carpenter et al., 2008) or results of 
genetic testing indicating AD susceptibility (Green et al., 2009), psychological distress, including 
depressive symptoms, do not significantly increase. These findings seem to be in line with the 
link between other types of genetic testing and related emotional consequences (Broadstock, 
Michie, & Marteau, 2000). One might surmise that these findings may be due to self-selection; 
individuals who might experience testing-related distress opt out of participation. 
Unfortunately, with regards to the prior depressive status of who might seek testing, less 
is known.  Studies exploring the factors associated with willingness to complete memory 
screening for MCI or dementia report mixed results in relation to depressive symptoms. One 
study explored intent to participate in screening for MCI in varying hypothetical scenarios, 
including: 1) subjective memory complaints; 2) no memory complaints; 3) or family member-
relayed memory concerns (Dale et al., 2008).  Findings were mixed, in that depressive symptoms 
were associated with less interest in memory screening only in the instance of hypothetical 
memory changes. Across groups, anxiety was not associated with willingness to participate in 
MCI screening. Another study examining interest in memory screening among individuals with 
actual subjective memory complaints found no significant difference in depressive symptoms 
between individuals who had sought help for memory concerns and those who had not (Hurt et 
al., 2012). Yet, diagnostic testing could be considered useful in teasing out whether memory 
symptoms are caused by depression or dementia. In one study exploring intent to participate in 
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predictive testing for AD, self-reported history of depression was a significant predictor (Green 
et al., 1997).  
Exploring the relationship between mental health and interest in AI may help tease out 
whether there is a need for pre-test counseling, inclusive of a significant focus on baseline 
distress. A systematic literature review examining the psychological implications of predictive 
genetic testing reported that in over half of studies reviewed, emotional status prior to testing was 
significantly related to level of distress following testing completion (Broadstock et al., 2000). It 
follows that a psychological assessment pre-testing may then help to better target post-test 
counseling support, as it has been documented that individuals with current depression may be 
more vulnerable to adverse effects of testing (Lerman et al., 2002). 
Given the literature base, the following hypotheses are derived: 1) for the full sample, 
having a psychiatric diagnosis will be significantly associated with AI interest and participation; 
and 2) for the subsample of individuals with dementia, presence of a psychiatric disorder will not 
be significantly associated with AI interest and participation.   
 
Informal care support relationship. Among individuals with dementia, care partner 
relationship may have implications for AI interest and participation, as the individual 
accompanying the patient to their cognitive assessment appointment(s) is likely also an important 
participator in the decision-making process for neuroimaging study involvement. One study, 
using an Alzheimer Disease Center registry cohort, examined caregiver willingness to have their 
loved one participate in an AD medication trial (Cary, Rubright, Grill, & Karlawish, 2015). The 
authors found that spousal care partners were significantly more likely to express research 
participation willingness and expressed a more positive attitude regarding research than adult 
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child care partners. The authors surmised that the finding might be due to greater time 
availability of spousal care partners and heightened interest in meaningful activities for the 
person with dementia. Based on the current research, we hypothesize that for the subsample of 
individuals with dementia, spousal care support will not be significantly associated with AI 
interest and participation. 
2.4  CONCLUSIONS 
Dr. Watson may be in the minority when it comes to interest in biomarker testing for 
Alzheimer’s disease, as, overall, there seems to be high interest in such testing. Given this level 
of receptiveness, examining the rates of interest in AI may be especially critical for anticipating 
and responding to the demand for AI. With the number of individuals and families anticipated to 
face AD growing exponentially, the number of those interested in AI can be expected to rise. The 
continued development of tools for dementia detection, in the earliest stages of illness, will help 
target treatments and care planning support to those who need it most.  
Modeling interest in AI offers some initial groundwork for understanding who is likely to 
be more accepting of such testing and, therefore, how to best develop protocols for pre- and post-
test counseling for individuals undergoing AI. These protocols would be grounded in a 
biopsychosocial framework that views the individual from a holistic perspective, acknowledging 
the biological and psychosocial factors that personify them.  The hypotheses derived above 
provide a premise for exploring the relationships between patient demographics, family history, 
and medical status variables with AI interest and participation. The following chapter will further 
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describe how these variables were operationalized and the sample from which they were derived, 
as well as present the analysis plan.    
 45 
3.0  METHODOLOGY 
3.1 STUDY DESIGN AND RATIONALE 
The focus of this dissertation was to: Aim 1) determine what biopsychosocial factors are 
significantly associated with interest in and participation in amyloid imaging research among 
registry participants at an Alzheimer Disease Center; and Aim 2) determine what 
biopsychosocial factors are significantly associated with interest in and participation in amyloid 
imaging research among a subsample of individuals diagnosed with dementia (IWDs). A 
secondary dataset comprised of baseline and aggregated longitudinal data from the University of 
Pittsburgh Alzheimer Disease Research Center (ADRC) and capturing all ADRC participants 
approached for an amyloid imaging (AI) research study from 2003-2013 was analyzed (N=449). 
This dataset provides a substantial sample of individuals who, fairly uniquely, have completed 
annual comprehensive cognitive assessments, range in their cognitive status, and have been 
queried at each assessment point regarding their willingness to participate in amyloid imaging 
research. Of note, social workers often facilitate the initial discussion with patients and families 
that explores interest in neuroimaging research. The full sample includes individuals with no 
cognitive impairment, mild cognitive impairment (MCI), or dementia to determine whether 
cognitive status is significantly related to AI interest or participation. To further explore 
significant associations with AI uptake among patients who have been the first and most frequent 
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users of such technology, a second set of analyses examined interest in amyloid imaging among 
a subset of individuals diagnosed with dementia. 
This dataset also allowed for greater delineation of interest in AI, via grouping into three 
levels of interest in AI participation: 1) amyloid imaging study participants (Participators); 2) 
individuals who declined amyloid imaging study participation but originally indicated interest in 
being contacted about imaging studies (Avoiders); and 3) individuals who did not want to be 
contacted for imaging studies or if they were first contacted regarding study participation, never 
agreed to an AI study (Refusers). These categories were derived from one or more contacts for 
each ADRC participant, in which they were either queried about their willingness to be contacted 
for a neuroimaging study or they were contacted about participation in an AI study. This 
approach allowed for the inclusion of all ADRC participants approached regarding AI studies 
from the time when recruitment for AI studies was first initiated. Three category groupings also 
allowed for a look at whether significant relationships with biopsychosocial factors varied by 
depth of interest in AI, rather than just participation.  For comparison, a second set of analyses 
examined significant associations between biopsychosocial factors and participation in AI, in 
which Participators were compared to Non-Participators (Avoiders and Refusers).  
The following sections provide detail on: 1) sample procedures, including the ADRC 
setting, sample description, and sampling strategy; 2) sources of data, including the data 
collection process and a description of each variable included in analysis; and 3) the data 
analysis plan. 
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3.2 PROCEDURES FOR SAMPLING 
3.2.1  Setting 
The ADRC is one of 29 federally-funded Alzheimer Disease Centers that conducts research with 
the goal of improving diagnosis and treatment for AD and other dementias. All centers offer 
comprehensive memory assessments for individuals who have concerns about their memory, as 
well as those who have no memory complaints but have an interest in memory research 
engagement. Individuals who participate in the ADRC registry complete annual memory 
evaluations that include neurological and psychiatric evaluations, brain imaging, a 
comprehensive neuropsychological assessment, and a psychosocial evaluation (Lopez, Becker, 
Klunk, Saxton, Hamilton, Kaufer, et al., 2000). Participation is voluntary and longitudinal. 
Participants and their family members may drop out from the ADRC at any time, although 
follow-up can continue until the death of the participant.  
To be eligible for participation in the ADRC, participants must: 1) be English speaking at 
an early age; 2) have a family member or friend who can attend the assessment and answer 
questions about the participant’s level of functioning (informant); 3) have a seventh grade or 
higher level of education; 4) have adequate visual and auditory abilities to complete 
neuropsychological testing; and 5) have no history of brain tumor or severe psychotic disorder. 
These requirements serve to enhance specificity and sensitivity of the final diagnosis. Almost all 
individuals are able to provide consent to ADRC participation. A minority assent to participation 
and an informant provides proxy consent. As a part of the consent process, all agree to their data 
being used by researchers who are ancillary to the ADRC. Following the memory evaluation, a 
multidisciplinary team of clinicians who assessed the participant meet to determine a diagnosis. 
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After an initial evaluation or when any change in diagnosis occurs following assessment, the 
participant and their family members are invited to return to the ADRC to meet with a 
neurologist and social worker to review the results of the assessment. At this time, in addition to 
discussion of treatment and social service support options, participants are also queried about 
their willingness to be contacted for neuroimaging studies at this time – a component of the 
outcome variable for this dissertation. Contact with an amyloid imaging study coordinator may 
also occur for individuals who are eligible for AI studies. 
3.2.2 Sample description 
Participants typically learn of the ADRC through doctor referral (primary care physician, 
neurologist, or psychiatrist) or self-refer after learning of the ADRC from internet searches, 
discussion with family/friends, or ADRC outreach programming. Individuals often initiate 
appointments due to memory concerns, although a cohort of individuals with no cognitive 
impairment enter the ADRC because of interest in dementia research or apprehension related to a 
family history of dementia.  
All individuals included in this dissertation study sample have completed at least one 
ADRC assessment and have received the results of the assessment. The following were criteria 
for dataset inclusion: 1) meeting the ADRC inclusion criteria described above; and 2) completing 
an ADRC assessment between 2003 (when recruitment for AI studies was initiated) and 2013; 
and 3) queried about neuroimaging study contact and/or AI study participation. Exclusion 
criteria include: 1) exclusion from the ADRC following the completion of an ADRC initial 
assessment; 2) expressing interest in neuroimaging study contact, but never being contacted for 
AI study participation.  
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Individuals who are contacted for an AI study may share the following experiences. At 
the time of a diagnostic meeting or during the annual assessment, they are asked whether they 
wish to be contacted regarding participation in brain imaging studies, which are primarily 
comprised of amyloid imaging protocols. During this discussion the clinician or social worker 
describes the general purpose and procedure typically expected for such studies. While there is 
no formal script, staff are trained to note (in lay terms) that neuroimaging studies are mainly 
comprised of protocols using an amyloid imaging positron emission tomography (PET) tracer, in 
most instances Pittsburgh Compound B (PiB). Participants are told that the purpose of amyloid 
imaging is to assess the usefulness of this tracer for diagnosing dementia at varying stages of the 
disease process. Any questions about what is described are addressed and typically include the 
length of study participation and risks associated with exposure to a radioactive tracer during 
PET imaging, or imaging itself. Individuals who agree to contact may then be contacted by an AI 
study coordinator. Those who refuse contact were included in the Refusers group for this 
dissertation. 
Within this study sample, individuals expressing interest in study contact were contacted 
by a study coordinator about participation in an AI study, and provided with further detail 
regarding study purpose and procedures. Studies may include one or more visits to complete 
amyloid imaging; in several instances participants complete up to three rounds of amyloid 
imaging over the course of three years. Additional procedures may also include other imaging 
and neuropsychological testing. As required with any consent protocol, the risks and benefits of 
study participation are described and the voluntary nature of study participation is emphasized. 
The risks described are those typically associated with participation in imaging (e.g. exposure to 
radioactivity, muscle aches from being immobile, anxiety from being in an enclosed space). 
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Risks also include the possibility of an unanticipated finding from imaging, such as the presence 
of a stroke or brain tumor. The study coordinator also emphasizes that there is no direct benefit 
gained from participation, although the aim of the study is to benefit society by improving our 
understanding of the relationship between beta-amyloid deposits and brain functioning. Those 
who agree to participation in an amyloid imaging study sign a consent form for the specific study 
and are deemed a Participator for the purpose of this dissertation. Those who refuse participation 
in an amyloid imaging study, after discussing the study with the coordinator, comprise the 
Avoiders group. A subset of individuals were contacted by the AI study coordinator between 
2003-2005, prior to the adoption process for determining willingness to be contacted. Individuals 
who refused any study participation during this time period were deemed Refusers.  
3.2.3 Sampling strategy 
A convenience sample was derived from the ADRC participant registry, applying the above 
eligibility criteria, and included all individuals with data documenting one or more queries about 
participation in an AI study, or contact regarding neuroimaging study participation, from 2003 
and through 2013. This approach allowed for the inclusion of a significant portion of individuals 
approached for AI research, over a range of study protocols that included individuals with 
different diagnoses. The study sample is derived from the ADRC registry sample, which is 
convenience in design and comprised of research-friendly individuals who have an interest in 
learning more about their cognitive functioning. 
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3.3 SOURCES OF DATA 
3.3.1 Data collection 
Three separate ADRC databases were accessed and merged to comprise the final dissertation 
dataset.  Independent variables were extracted from two datasets, including the National 
Alzheimer’s Coordinating Center Uniform Data Set (NACC UDS). Standardized clinical and 
neuropathological research data comprise the NACC UDS database and were collected by 
NACC-trained clinicians. For the purposes of this dissertation, only NACC UDS data collected 
by the University of Pittsburgh ADRC was accessed. In addition to UDS data, diagnostic data, 
including cognitive and psychiatric disorder diagnoses, were extracted from the University of 
Pittsburgh ADRC Registry. Diagnostic data extracted from the ADRC Registry were matched to 
UDS data by ADRC participant unique identifier and assessment date. Data collection using the 
UDS was initiated in 2005. Therefore, approximately half of the sample (n=251; 55.9%) have 
initial assessment data collected via UDS measures. For individuals who were ADRC 
participants prior 2005, their first annual assessment data collected via the UDS were instead 
extracted. 
Data for the dependent variables, AI interest and participation in amyloid imaging, were 
extracted for each participant from the ADRC Ancillary Study dataset for the given time period 
(2003-2013). While amyloid imaging studies initiated recruitment in 2003, tracking of interest in 
being contacted for neuroimaging studies did not start until 2006. This impacted the criteria used 
to determine assignment to amyloid imaging interest categories, as it included a subset of 
individuals who were asked about participating in an AI study before being queried about 
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willingness to be contacted for neuroimaging research. Figure 1 provides a flowchart illustrating 
the criteria system used, which will also be described in more detail in the next section.    
3.3.2 Study variables and operationalization 
Table 1 summarizes the dependent variables and each independent variable under investigation, 
while the following sections provide further description for each variable, including how each is 
measured. Several categorical variables had additional response options (e.g. race, education, 
ADRC diagnosis, modified Charlson Comorbidity Index, and care support relationship). While 
this table presents the final categories examined in bivariate and multivariate analysis, the full set 
of categories for each is examined in descriptive analysis. Reasons for category aggregation are 
discussed in the Results section. 
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Table 1. Description of variables 
Variable List Variable Type Variable Description Data Source 
Dependent Variables 
Interest in amyloid 
imaging research 
Categorical 1=participated in amyloid imaging 
(“Participators”); 2=declined amyloid 
imaging participation but initially indicated 
interest in being contacted about brain 
imaging (“Avoiders”); and 3=did not want 
to be contacted for imaging studies 
(“Refusers”) 
ADRC 
Ancillary 
Database 
Participation in amyloid 
imaging research 
Dichotomous 1=participated in amyloid imaging 
(“Participators”); 0=did not participate in 
amyloid imaging (“Non-Participators”) 
ADRC 
Ancillary 
Database 
Independent Variables  
Demographics       
Age Continuous Age at assessment visit, years UDS 
Sex Categorical 0=Female; 1=Male UDS 
Race Categorical 0=White; 1=African American UDS 
Education Categorical 1=Less than HS/HS/GED 
2=Some college/ Associate’s/Bachelor’s 
3=Graduate work/Graduate degree 
UDS 
Cognition       
ADRC diagnosis Categorical 1=no cognitive impairment 
2=mild cognitive impairment 
3=dementia 
ADRC 
Registry 
Mini Mental State Exam Continuous Global measure of cognitive impairment 
(potential range 0-30) 
UDS 
Age at onset of symptoms Continuous Reported age when symptoms began (for 
those diagnosed with cognitive impairment) 
UDS 
Change in ADRC 
diagnosis 
Dichotomous 0=no change in diagnosis; 1=change in 
diagnosis 
ADRC 
Registry 
Health Status       
Modified Charlson 
Comorbidity Index 
Dichotomous 0=Absence of physical health comorbidity; 
1=presence of physical health comorbidity 
UDS 
Psychiatric diagnosis Dichotomous 
Presence or absence of a psychiatric disorder 
(0=No; 1=Yes) 
Electronic 
ADRC 
Registry 
Family History       
First degree family 
members diagnosed with 
dementia  
Dichotomous 0=No; 1=Yes UDS 
Care Support*       
Care partner relationship Categorical 1=Spouse/Partner; 2=Adult child; 3=Other UDS 
 
    Note: *Care support relationship was analyzed only for individuals with dementia. 
    ADRC=Alzheimer Disease Research Center; HS=high school; GED=General Equivalency Diploma 
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Dependent variable: Interest in amyloid imaging 
The variable of focus measures level of interest in amyloid imaging and is a three-level, 
categorical variable where: 1=amyloid imaging participants (“Participators”); 2=individuals 
initially indicated interest in being contacted about neuroimaging studies, but later declined 
amyloid imaging participation (“Avoiders”); and 3=individuals who did not want to be contacted 
for imaging studies or, if first queried about study participation, always refused (“Refusers”). 
(See Figure 2 for a flowchart illustrating interest category determination.) All participants were 
queried about study contact and/or study participation at least once throughout the course of their 
ADRC participation between 2003 and 2013.  
 
Dependent variable: Participation in amyloid imaging 
Participation in amyloid imaging was aggregated from the variable measuring interest in 
amyloid imaging. While the category Participators remains the same, Avoiders and Refusers 
were collapsed into one category, Non-Participators. This allowed for examining whether 
biopsychosocial factors significantly related to interest in AI differed in comparison to factors 
significantly related to AI participation.   
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Figure 2. Process for determining amyloid imaging (AI) interest level groupings among a sample of ADRC 
participants completing one or more cognitive assessments from January 2003 through October 2013 
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For the full sample, independent variables were categorized into five groups: 
Demographic variables (age, sex, race, education); Cognition variables (ADRC diagnostic group, 
Mini Mental State Exam score, change in ADRC diagnosis, age at onset of cognitive decline); 
Health (presence of psychiatric diagnosis, modified Charlson Comorbidity Index score); and 
Family history of dementia. Additional variables included in modeling of the subsample of IWDs 
were the Cognition variable, age at onset of cognitive symptoms, and Care support relationship. 
Modeling for IWDs omitted ADRC diagnosis.  
 
Demographic variables 
Demographics, including age, sex, race, and education level were extracted for all 
individuals included in the sample. Age (measured in years), sex (0=Female; 1=Male), race 
(0=White; 1=African American), and education (1=Less than high school, high school diploma, 
general equivalency diploma; 2=Some college, Associate’s degree, Bachelor’s degree; 
3=Graduate work, graduate degree) were collected as a component of the social work 
assessment, and included in the UDS dataset. All other demographic data for each ADRC 
registry participant were collected from the initial assessment or the first annual assessment 
using the UDS. 
 
Cognition variables 
 Cognitive status was captured through several variables, including: diagnostic group 
(1=dementia; 2=mild cognitive impairment ; 3=no cognitive impairment); and Mini Mental State 
Exam score (MMSE; Folstein, Folstein, & McHugh, 1975); age at onset of cognitive changes; 
and change in ADRC diagnosis (0=no change; 1=change in diagnosis). Diagnostic group was 
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extracted from the ADRC database and was determined by faculty/staff consensus for each 
participant assessment. Change in ADRC diagnosis was created using diagnostic data from: 1) 
the initial visit (data that is the primary focus of this dissertation); 2) the first assessment where 
data on interest in AI was also first collected (if it differed from the initial assessment visit); and 
3) the last assessment completed by each study participant within the timeframe under 
investigation. Individuals converting from no cognitive impairment, mild cognitive impairment 
(MCI), or dementia to a different diagnosis, using the same three diagnostic categories, were 
deemed to have experienced a diagnostic change. ADRC diagnostic data were collected via the 
ADRC Registry. Age of onset was determined at the initial visit for all individuals reporting 
cognitive symptoms and collected as a part of the UDS system. This variable was included only 
in analysis for the subset of IWDs, as the full sample includes ADRC participants with no self-
report of cognitive impairment.  
The Mini Mental State Exam, administered by a trained neuropsychomotrist, is a global 
measure used to assess neurocognitive functioning and tests patients on memory, orientation, 
language, recall and attention (Folstein, Folstein, & McHugh, 1975). Scores range from 0 to 30 
with higher scores indicative of less cognitive impairment. A review study reported satisfactory 
reliability and construct validity, as well as high levels of sensitivity for moderate to severe 
levels of cognitive impairment (Tombaugh & McIntyre, 1992). MMSE data were collected as a 
part of the UDS dataset. 
 
Health status variables 
 UDS-based physical health history data were collected during the medical component of 
the ADRC assessment and were used to determine participant scoring on a modified version of 
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the Charlson Comorbidity Index (CCI; Charlson, Pompei, Ales, & MacKenzie, 1987; Gill, 
Koepsell, Hubbard, & Kukull, 2011).  The CCI is a weighted index for classifying medical 
comorbidities according to number of comorbidities and severity of illness. Gill et al. (2011) 
applied a modified version of the CCI to UDS data, in which four comorbid conditions (cardiac 
arrest, congestive heart failure, cerebrovascular disease, and diabetes) were included with 
assigned weights of 1 for each condition. CCI scores range from 0 (no conditions) to 4 (all 
conditions). Although this modified version excludes comorbid conditions listed in the full 
version of the CCI because they are not collected by the UDS, most of the more severe 
conditions in the CCI would mean exclusion from the ADRC registry (e.g. tumor, leukemia, 
lymphoma, AIDS), and are therefore not applicable. The modified CCI was dichotomized for 
analysis purposes, where 0=no conditions and 1=1 or more conditions. 
Mental health status was measured by the dichotomous variable, presence of psychiatric 
diagnosis, which was determined for each participant at the ADRC consensus meeting and based 
on ADRC psychiatric assessment data. Psychiatric diagnostic coding captures any presence of 
depression, anxiety, or other mental health diagnosis. This data was extracted from the ADRC 
Registry data. 
 
Family history of dementia 
A dichotomous variable indicating whether the participant has any immediate relative 
(parents, siblings, or children) with a diagnosis of dementia was extracted from UDS data. This 
variable was aggregated from an in-depth interview on family history completed as a part of the 
social work assessment. Family history of dementia is a key risk factor for developing the 
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disease and many ADRC participants point to their own family history as a prime motivator for 
completing an ADRC memory assessment.  
 
Care support relationship 
For the subsample of individuals with dementia, care partner relationship to ADRC 
participant will be extracted from the UDS dataset. Categories for care support relationship are 
1=Spouse or partner; 2=Adult child; and 3=Other relationship. 
3.4 DATA ANALYSIS PLAN 
3.4.1 Descriptive analyses 
Descriptive analyses were conducted to characterize the full sample and subsample of IWDs. For 
amyloid imaging interest and each categorical independent variable, frequencies were calculated. 
For continuous independent variables (age, MMSE, age at onset of cognitive symptoms), means 
and measures of dispersion (standard deviation, range, and skewness) were examined. Each 
continuous independent variable was examined for normality of distribution.  Of note, according 
to Shapiro-Wilk testing, normality was violated for each continuous variable (See Table 2). One 
outlier in both age and age at onset of decline was present the Participators group and subsample 
of IWDS. This individual was kept in the sample throughout analysis because they represented 
an accurate addition to sample composition. Bivariate and multivariate analyses including and 
excluding this case resulted in no differences in significant findings. In preparation for bivariate 
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and multivariate analyses, frequencies of each categorical variable were analyzed and levels 
were collapsed for variable categories with small cell sizes, as appropriate.    
 
 
 
Table 2.  Test of normality for age, Mini Mental State Exam score, and age at onset of cognitive decline in 
the full sample 
Continuous variables Shapiro-
Wilk W 
df p 
Age .98 49 <.001 
MMSE score .92 49 <.001 
Age at onset of cognitive decline .97 58 <.001 
 
 
 
3.4.2  Bivariate analyses 
Amyloid imaging interest groups – Participants, Avoiders, and Refusers – and each independent 
variable were compared across each biopsychosocial factor (independent variable) for the full 
sample and subset of IWDs. According to the Shapiro-Wilk W test, for the full sample the 
normality assumption for was not met for the Refusers group (See Table 3). Mean MMSE scores 
also violated the normality assumption for each AI interest group. When examining normality 
across groups for the IWD subsample, normality was not met for the Refusers group for age, 
MMSE score, or age at onset of cognitive decline (See Table 4). Although normality violations 
occurred, this dissertation continued with one-way fixed effects analysis of variance (ANOVA), 
as cell sizes were large and previous work points to a robustness of ANOVA, even when this 
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assumption violation occurs (Schmider, Ziegler, Danay, Beyer, & Bühner, 2015). For significant 
ANOVA findings, the pattern of differences in the continuous variable across amyloid imaging 
interest groups was examined with post hoc pairwise comparisons using the Scheffé adjustment. 
To support ANOVA findings, Kruskal-Wallis H tests were also used. Continuous variable 
distributions were dissimilar across AI interest groups, for the full sample and dementia 
subsample, as assessed by visual examination of boxplots. Therefore frequency distributions 
rather than medians were compared. In instances where significant differences resulted in 
frequency distributions, pairwise comparisons were performed using Dunn’s procedure with a 
Bonferroni correction for multiple comparisons. Chi-square testing was used for each categorical 
variable in all instances when at least 80% of cells had frequencies of 5 or more. When cell sizes 
did not meet this criteria, Fisher’s exact test was applied rather than chi-square testing. 
 
 
 
Table 3. Test of normality for age and MMSE score for each amyloid imaging interest group, for the full 
sample 
 Age MMSE 
AI Interest 
Group 
Shapiro-
Wilk W 
df p Shapiro-
Wilk W 
df p 
Refusers .96 209 <.001 .95 209 <.001 
Avoiders .96 42 .15 .88 42 <.001 
Participators .99 198 .12 .88 198 <.001 
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Table 4. Test of normality for age, MMSE score, and age at onset of cognitive decline for each amyloid 
imaging interest group, for the subsample of individuals with dementia  
 Age MMSE Age at onset 
AI Interest 
Group 
Shapiro-
Wilk W 
df p Shapiro-
Wilk W 
df p Shapiro-
Wilk W 
df p 
Refusers .94 146 <.001 .97 146 .001 .93 146 <.001 
Avoiders .97 24 .60 .93 24 .08 .95 24 .25 
Participators .98 90 .27 .97 90 .03 .98 90 .20 
 
 
 
 
Additionally, two AI participation groups, Participators and Non-Participators, were 
compared for each biopsychosocial factor. Shapiro-Wilk W tests for the full sample revealed 
normality assumption violations in mean age for Non-Participators and mean MMSE score for 
both Participators and Non-Participators (See Table 5).  For the IWD subsample, normality was 
violated for mean age, mean MMSE score, and mean age at onset of cognitive decline only for 
Non-Participators (See Table 6). Independent samples t-tests were completed to compare each 
continuous variable by AI participation group. While normality violations occurred, the 
robustness of the t-test may hold in the case of larger sample sizes (greater than 40) (Lumley, 
Diehr, Emerson, & Chen, 2002). To support t-test findings, Mann-Whitney U tests were also 
applied for two-group comparisons to continuous variables. As with the three-group 
comparisons, distributions of age and MMSE score for the full sample, and age, MMSE score, 
and age at onset of cognitive symptoms for IWDs, were dissimilar for each continuous variable 
and across AI participation groups, as assessed by visual inspection of boxplots. Therefore 
frequency distributions rather than medians were compared. As in the case of three-group 
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comparisons, chi-square testing was used for each categorical variable when at least 80% of cells 
had frequencies of five or more. Fisher’s exact test was applied when cell sizes violated this rule. 
 
 
 
Table 5. Test of normality for age and MMSE score for each amyloid imaging participation group, for the 
full sample  
 Age MMSE 
AI Interest 
Group 
Shapiro-
Wilk W 
df p Shapiro-
Wilk W 
df p 
Non-Participators .962 251 .000 .945 251 .000 
Participators .989 198 .116 .884 198 .000 
 
 
 
 
Table 6. Test of normality for age, MMSE score, and age at onset of cognitive decline for each amyloid 
imaging participation group, for the subsample of individuals with dementia  
 Age MMSE Age at onset 
AI Interest 
Group 
Shapiro-
Wilk W 
df p Shapiro-
Wilk W 
df p Shapiro-
Wilk W 
df p 
Non-Participators .946 170 .000 .967 170 .000 .935 170 .000 
Participators .983 90 .274 .969 90 .029 .980 90 .195 
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To address low cell sizes and to prepare for multivariate analysis, several variables were 
aggregated for bivariate analysis, as presented in Table 1. Education level was aggregated to 1.) 
Less than high school/high school diploma/GED, 2.) Some college/Associate’s degree/ 
Bachelor’s degree, and 3.) Graduate work/Graduate degree. Additionally, due to low cell 
frequencies, bivariate analysis included a comparison of only African American and white 
individuals. For the dementia subsample, care support relationship was collapsed to 1) 
Spouse/partner, 2) Adult children, and 3) Other (sibling, other relative, friend/neighbor, paid 
caregiver/provider, other – not specified). 
3.4.3 Multivariate analyses 
Due to the categorical nature of the dependent variable, multinomial logistic regression and 
binomial logistic regression were completed to model biopsychosocial factor associations with 
amyloid imaging interest and participation, respectively. One benefit of logistic regression is that 
is does not assume normality, linearity, or homoscedasticity. For the full sample, two models 
were run for each regression type to address the potential for multicollinearity between ADRC 
diagnostic group and MMSE score. For the subsample of IWDs one model was run using each 
regression approach.  
Multivariate logistic regression included interest in amyloid imaging as the dependent 
variable comparing the groups, Refusers, Avoiders, and Participators. Refusers served as the 
reference group. The first multivariate run for the full sample (Model 1a) included the 
independent variables: Demographics (age, sex, race, and education level); Cognition (ADRC 
diagnosis and change in ADRC diagnosis); Health (presence of psychiatric diagnosis and 
presence of physical health comorbidity); and Dementia family history.  The second multivariate 
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model (Model 1b) included MMSE score in place of ADRC diagnosis. Modeling for the 
dementia subsample (Model 3) included the following independent variables: Demographics 
(age, sex, race, and education level); Cognition (MMSE and age at onset of cognitive 
symptoms); Health (psychiatric diagnosis and presence of physical comorbidity); Dementia 
family history; and Care Support Relationship.   
Binomial logistic regression examined biopsychosocial factors significantly associated 
with participation in amyloid imaging, comparing Participators to Non-Participators, and with 
Non-Participators serving as the reference group. For the full sample, two models were again run 
(Models 2a and 2b), mirroring the multinomial logistic regression modeling described above 
(Model 1a and 1b, respectively). Binomial logistic regression modeling (Model 4) for the 
subsample of IWDs was the same as that used in the multivariate modeling described above 
(Model 3). 
All assumptions were met for completing logistic regression analysis, including a linear 
relationship between the continuous independent variables included in the model and the logit of 
the dependent variable, interest in amyloid imaging for multinomial logistic regression, and 
participation in amyloid imaging for binomial logistic regression. No outliers were identified 
after examining the influential statistics, leverage, Cook’s distance, and Dfbeta values, for each 
regression model. Additionally, the potential for multicollinearity was assessed with no 
independent variables included in modeling noted to be redundant. 
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4.0  RESULTS 
4.1 OVERVIEW OF RESULTS 
Three sections comprise the results chapter. The first includes descriptive results for the 
dependent variable under investigation, interest in amyloid imaging, as well as descriptive 
findings for the full sample and the subsample of individuals with dementia (IWDs). Second, 
bivariate and multivariate analyses address the first research objectives: Examine what 
psychosocial factors were significantly associated with level of interest in and participation in 
amyloid imaging. The third section presents bivariate and multivariate results addressing the 
second research objectives: Among individuals with dementia, examine what psychosocial 
factors were significantly associated with level of interest in and participation in amyloid 
imaging.   
4.2 DESCRIPTIVE FINDINGS 
4.2.1 Interest in amyloid imaging study participation 
A total of 449 Alzheimer Disease Research Center (ADRC) participants were queried regarding 
their interest in participation in an amyloid imaging (AI) study between 2003 and 2013. Table 1 
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presents the number and percentages of individuals comprising each AI interest group, for all 
ADRC participants and the subset of participants diagnosed with dementia. Participators, 
individuals who completed an AI study, and Refusers, those who refused any AI study contact or 
participation, comprised similarly sized groups (n=198, 44.1% and n=209, 46.5%, respectively; 
See Table 7). Avoiders, individuals who expressed initial interest in contact regarding AI studies, 
yet later refused participation, accounted for just 9.4% (n=42) of the sample. Among IWDs, a 
larger number comprised the Refusers group (n=146, 56.4%), compared to Participators (n=90, 
34.4%) and Avoiders (n=24, 9.3%). 
 
 
 
Table 7. Grouping of interest in amyloid imaging research participation  
  All Participants  
(N=449) 
Participants with Dementia 
(n=260) 
AI Interest 
Group 
Frequency % Frequency % 
Refuser 209 46.5 146 56.2 
Avoider 42 9.4 24 9.2 
Participator 198 44.1 90 34.6 
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A minority of the sample altered their opinion regarding AI study contact or AI study 
participation (See Table 8). Approximately one fifth of the sample changed interest in being 
contacted regarding an AI study (n=86, 19.2%), while fewer IWDs changed their interest in 
contact (n=39, 15%). Smaller numbers of individuals fluctuated in their actual AI participation; 
when change occurred, more individuals participated in a study, then later refused participation, 
rather than refusing first and then participating (n=16, 3.6% vs. n=2, 0.4%). The same was true, 
albeit in smaller frequencies, for IWDs (n=7, 2.7% vs. n=2, 0.8%). 
 
 
 
Table 8. Amount of fluctuation in amyloid study interest and participation 
  
All Participants (N=449) Participants with 
Dementia (n=260) 
  Frequency % Frequency % 
Changed interest in contact 86 19.2 39 15.0 
Changed interest in study participation 18 4.0 9 3.5 
         Participated, then refused participation 16 3.6 7 2.7 
         Refused participation, then participated 2 0.4 2 0.8 
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4.2.2 Descriptive results for the full sample 
The following independent variables characterized the study sample (N=449) and comprised the 
psychosocial factors under investigation in relation to AI interest and participation. Table 9 
presents frequencies and percentages for categorical variables, as well as means and standard 
deviations for continuous variables. Independent variables were categorized into five groups: 
Demographic variables (age, sex, race, and education level); Cognition variables (ADRC 
diagnostic group, Mini Mental State Exam score, change in ADRC diagnosis, and age at onset of 
cognitive decline); Health (presence of psychiatric diagnosis and modified Charlson Comorbidity 
Index score); Family history of dementia; and Care support relationship to the patient.  
 
Demographic variables 
Older adults comprise the majority of the sample (Mean age=72.93 years, Standard 
Deviation=9.71), with over three-quarters over age 65. Half of participants are women (53.7%), 
and a large majority of the sample is white (91.1%). Other racial groups in the sample, 
unfortunately in small numbers, include individuals who identify as African American (7.3%), 
Asian (0.7%), and Multiracial (0.9%). Due to these small numbers, multivariate analysis which 
includes race as an independent demographic variable, is limited to African American and white 
individuals.  
Finally, educational attainment was high; almost half of the sample completed a 
Bachelor’s degree (16.0%) or graduate work/graduate degree (30.1%). Just 5.6% did not 
complete high school, while over one quarter completed high school or their General 
Equivalency Degree (GED; 26.7%), and one fifth completed some college or an Associate’s 
degree (20.3%). To create more equal groupings for analysis, education was aggregated for 
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bivariate and multivariate analysis to the following groups: less than high school/high school 
diploma or GED (32.3%); some college or Associate’s degree/Bachelor’s degree (36.3%); and 
graduate work or graduate degree (31.4%).  
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Table 9. Biopsychosocial factors for the full sample and subsample of individuals with dementia 
  
Full Sample 
(N=449) 
Subsample of IWDs 
(n=260) 
Demographics 
 
 Age, Mean (SD), Range 72.93 (9.71), 36-97 74.75 (9.90), 36-97 
Sex, n (%)        Female 241 (53.7) 139 (53.5) 
     Male 208 (46.3) 121 (46.5) 
Race, n (%) 
       African American 33 (7.3) 15 (5.8) 
     Asian 3 (0.7) 1 (0.4) 
     Multiracial 4 (0.9) 3 (1.2) 
     White 409 (91.1) 241 (92.7) 
Education, n (%) 
       Less than HS 25 (5.6) 21 (8.1) 
     HS or GED 120 (26.7) 87 (33.5) 
     Some college/Associate's degree 91 (20.3) 55 (21.2) 
     Bachelor's degree 72 (16.0) 38 (14.6) 
     Graduate work/Graduate degree 141 (31.4) 59 (22.7) 
Cognition 
  ADRC diagnosis, n (%) 
       Normal 84 (18.7) 
      MCI 105 (23.4) 
      Dementia 260 (57.9) 260 (100.0) 
MMSE Score, Mean (SD), Range 24.14 (4.90), 4-30 21.39 (4.49), 4-30 
Change in ADRC diagnosis, n (%) 
  No change 377 (84.4) 256 (98.5) 
Normal to MCI 6 (1.3) 
 Normal to Dementia 9 (2.0) 
 MCI to Dementia 38 (8.5) 
 MCI to Normal 12 (2.7) 
 MCI to Dementia to MCI 1 (0.2) 
 Dementia to MCI 4 (0.9) 4 (1.5) 
Age at Onset of Cognitive Symptoms*, Mean (SD),    
       Range 68.85 (9.72), 34-92 70.11 (9.43), 34-92 
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Table 9. (continued)  
  
Full Sample 
(N=449) 
Subsample of 
IWDs 
(n=260) 
Health 
  Psychiatric diagnosis, n(%) 142 (31.6) 90 (34.6) 
Modified CCI Score, n(%) 
      0 330 (73.5) 185 (71.4) 
    1 89 (19.8) 57 (21.9) 
    2 24 (5.3) 13 (5.0) 
    3 5 (1.1) 5 (1.9) 
    4 0 (0.0) 0 (0.0) 
Family History 
  Family history of dementia, n(%) 237 (52.8) 132 (50.8) 
     Unknown 1 (0.2) 1 (0.4) 
Care Support 
  Relationship to patient**, n(%) 
       Spouse/partner 267 (59.5) 154 (59.2) 
     Child 110 (24.5) 89 (34.2) 
     Sibling 8 (1.8) 5 (1.9) 
     Other relative 10 (2.2) 7 (2.7) 
     Friend/neighbor 13 (2.9) 3 (1.2) 
     Paid caregiver/provider 1 (0.2) 0 (0.0) 
     Other 5 (1.1) 2 (0.8) 
     Missing 35 (7.8) 0 (0.0) 
Notes: *91 participants did not report memory symptoms; 78 had a diagnosis of Normal; 13 had a 
diagnosis of MCI 
**35 participants did not have an informant; 34 had a diagnosis of Normal; 1 had a diagnosis of 
Mild Cognitive Impairment 
ADRC: Alzheimer Disease Research Center; CCI: Charlson Comorbidity Index; IWD: 
Individuals with dementia; MCI: Mild cognitive impairment; SD: Standard deviation 
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Cognition variables 
Over half of the sample had a diagnosis of dementia (57.5%), while 23.4% had a 
diagnosis of mild cognitive impairment (MCI) and 18.7% had no cognitive impairment. 
Dementia diagnoses included probable Alzheimer’s disease (AD; n=212, 81.4%) and possible 
AD (n=9, 3.6%). While probable AD infers that other potential causes of dementia have been 
ruled out, a diagnosis of possible Alzheimer’s disease is given when the diagnostic team believes 
that dementia may be due to another cause. Among those diagnosed with possible AD, 
cerebrovascular disease (n=4), preceding and concurrent depression (n=1), head injury (n=1), 
frontotemporal dementia (n=1), and other (non-specified) conditions (n=2) were dual diagnoses. 
Other dementia diagnoses included multiple infarct dementia (n=1, 0.4%), frontotemporal 
dementia (n=14, 5.4%), other (non-specified and unknown) dementias (n=16, 6.1%), and Lewy 
Body dementia (n=8, 3.1%). Among those with a non-specified dementia, six had a concurrent 
psychiatric diagnosis and three were diagnosed with cerebrovascular disease, both of which may 
contribute to a presentation of dementia symptoms.  
Greater specificity of diagnosis also occurred for patients diagnosed with mild cognitive 
impairment. Amnestic MCI was the primary diagnosis (n=90, 85.7%), while a minority were 
diagnosed with non-amnestic MCI (n=15, 14.3%). Among patients diagnosed with no cognitive 
impairment, the majority (n=67, 79.8%) were controls; they neither reported nor exhibited any 
cognitive impairment symptoms. Within this subgroup of controls, it is worth noting that one 
participant had cerebrovascular disease and one had a head injury.  A minority within the no 
cognitive impairment group also exhibited or reported symptoms, though not to the point of 
warranting a cognitive impairment diagnosis. Four (5.6%) had abnormal test scores yet no 
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subjective complaint, while 13 (15.5%) had complaints of cognitive problems yet normal 
scoring.  
Mean Mini Mental State Exam (MMSE) score was in the mild impairment range for the 
sample (Mean = 24.14; Standard Deviation=4.90). Scores ranged from 4 to 30, with 11.8% 
(n=53) obtaining a perfect score (30), indicating a ceiling effect. Overall, 15.6% (n=70) of the 
sample experienced a change in ADRC diagnosis over the timespan in which amyloid study 
participation was examined. Change in diagnosis in most cases followed a typical negative 
trajectory of disease progression, including transitions from MCI to dementia (n=38, 8.5%), 
normal to dementia (n=9, 2.0%), or normal to MCI (n=6, 1.3%). Interestingly, there was also a 
handful of participants who “improved” in diagnosis. Twelve participants (2.7%) transitioned to 
having no cognitive impairment following an initial MCI diagnosis, and four (0.9%) transitioned 
from dementia to MCI. Just one participant (0.2%) experienced two diagnostic changes, from 
MCI to dementia, and back to MCI. 
Finally, self- and/or informant-reported mean age at onset of cognitive symptoms was in 
the older adult range (Mean=68.85, Standard Deviation=9.72), and age at onset ranged from 34 
to 92 years. Values for this variable were available only for those who reported cognitive 
symptoms (n=358). One outlier (34 years at onset) was identified.  
 
 
Health variables 
Of the full sample, 31.6% (n=142) had a psychiatric diagnosis identified by the ADRC. 
This diagnosis could be current and active or a past condition in remission and most commonly 
represented a depression or anxiety disorder. A modified Charlson Comorbidity Index (CCI) 
score was calculated for each participant, indicating the presence and severity of physical health 
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comorbidities. The sample was predominantly free of comorbidity (n=330, 73.5%). As scoring 
on the CCI increased, the percentage of individuals with each score declined; 19.8% (n=89) had 
a comorbidity score of one, 5.3% (n=24) had a score of two, 1.1% (n=5) had a score of three, and 
no participants scored four. 
 
 
Dementia family history variable 
Just over half of the sample reported a family history of dementia (n=237, 52.8%), 
indicating they had one or more first degree relatives (e.g. parents, siblings, or children) with 
dementia. 
 
Care support relationship variable 
Informant, or care support, relationships were predominantly spousal or partner (n=267, 
59.5%), while almost one-quarter were adult children relationships (n=110, n=24.5%). Other 
included siblings (n=8, 1.8%), other relatives (n=10, 2.2%), friends or neighbors (n=13, 2.9%), 
paid caregivers (n=1, 0.2%), or other relations (n=5, 1.1%). A proportion of sample did not 
participate in the ADRC with an identified informant (n=35, 7.8%); most (n=34) had a diagnosis 
of no cognitive impairment. Although the current criteria for ADRC participation requires that 
participants are accompanied by an informant, long-time control participants (healthy volunteers 
with no cognitive impairment) were “grandfathered” in to the ADRC registry and encouraged, 
but not required, to have an accompanying informant. The protocol follows that if an ADRC 
control participant transitions to a cognitive impairment diagnosis, an informant must also 
participate in the diagnostic process. Due to missing data, predominantly comprising the 
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diagnostic group with no cognitive impairment, this variable was not included in bivariate and 
multivariate analysis for the full sample. Informant relationship is included in further analysis for 
the dementia subsample, and referred to as care support relationship, since in this subsample 
informants also have care partnering, or caregiving, relationships with the patient. 
4.2.3 Descriptive results for the subsample of individuals with dementia 
Demographic variables 
As expected, mean age for IWDs was higher than for the full sample (Mean=74.75, Standard 
Deviation=9.90), and ages ranged from 36-97 years. An outlier (age 36 years) was also present in 
the dementia subsample. Similar to the full sample, women comprised the majority of the 
dementia subsample (n=139, 53.5%), and whites (n=241, 92.7%). African Americans were the 
second largest racial group (n=15, 5.8%), while the remaining racial groups represented were 
Asian (n=1, 0.4%) and Multiracial (n=3, 1.2%).  
Compared to the full sample, educational attainment was lower among IWDs. Smaller 
percentages had completed a Bachelor’s degree (14.6%, n=38) or graduate work/graduate degree 
(22.7%, n=59), while a similar percentage had completed some college or an Associate’s degree 
(n=21.2%, n=55). A larger percentage of IWDs compared to the full sample had completed high 
school or obtained a GED (33.5%, n=87), or had less than a high school degree (8.1%, n=21). 
 
Cognition variables 
A description of the types of dementia included in this subsample was provided in the 
previous section (See Section 4.2.2). As noted, a large majority were diagnosed with probable 
Alzheimer’s disease (81.4%).  Mean MMSE score for IWDs was in the mild to moderate 
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impairment range (Mean=21.39, Standard Deviation=4.49) and scores ranged from four to 30. 
Mean age at onset of cognitive symptoms was 70.11 years (Standard Deviation=9.43) and ages 
ranged from 34 to 92 years. As with the full sample, an outlier with age of onset beginning at 34 
years is included in this subsample.  
 
Health variables 
As with the full sample, approximately one-third of the dementia sample was diagnosed 
with a psychiatric disorder by ADRC clinicians (n=90, 34.6%). Modified CCI scores shared a 
similar distribution with the full sample. The majority of the sample scored 0, or had an absence 
of comorbidity (n=185, 71.4%). Over one quarter (28.8%, n=75) of the sample scored one or 
more on the index and as before percentages of individuals with each score decreased as CCI 
score increased (1=21.9%; 2=5.0%; 3=1.9%; 4=0.0%).  
 
Dementia family history variable 
As with the full sample, approximately half of the subsample of individuals with 
dementia had a first degree relative with dementia (50.8%, n=132). 
 
Care support relationship variable 
Relationships with care support were predominantly comprised of spouses or partners 
(n=154, 59.2%), followed by adult children (n=89, 34.2%).  The remaining relationships 
included siblings (n=5, 1.9%), other relatives (n=7, 2.7%), friends or neighbors (n=3, 1.2%), and 
other relations (n=2, 0.8%).  
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4.3 BIOPSYCHOSOCIAL FACTORS ASSOCIATED WITH AMYLOID IMAGING 
INTEREST AND PARTICIPATION FOR THE FULL SAMPLE 
This section addresses the research objective of examining biopsychosocial factors associated 
with interest in amyloid imaging for dementia diagnosis. Results of bivariate analyses are first 
described, comparing differences in AI interest groups (Refusers, Avoiders and Participators) for 
each biopsychosocial variable. Next, bivariate findings comparing Participators to Non-
Participators (Refusers and Avoiders) are presented.  
The results of four logistic regression models are presented. The first two models (Model 
1a and Model 1b) apply multinomial logistic regression to examine factors associated with three 
amyloid interest groups. Refusers serve as the referent group, to which Participators and 
Avoiders are compared. Model 1a includes the cognition variable ADRC diagnosis (normal, 
MCI or dementia), while Model 1b uses the variable MMSE score in place of diagnosis. Two 
binomial logistic regression models follow (Model 2a and Model 2b), which again compare 
Participators to Non-Participators (referent group). As with multinomial logistic regression, 
Model 2a includes ADRC diagnosis and Model 2b uses MMSE score.  
The full sample was limited to African Americans and whites, due to low cell frequencies 
for Asian (n=3) and Multiracial (n=4) individuals. Additionally one case (a Refuser) was missing 
data for dementia family history and a second case was missing comorbidity data, limiting 
multivariate analysis to N=440.  
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4.3.1 Bivariate findings for the full sample 
Bivariate comparisons of Refusers, Avoiders and Participators 
Table 10 presents bivariate findings comparing three AI interest groups. Although interpreted 
with caution due to normality violations, there was a significant difference in age across groups, 
F(2, 446)=18.75, p <.001, η2=.08. In post hoc pairwise comparisons, Participators (M= 69.88, 
SE=.66) were significantly younger than both Refusers (M=75.34, SE=.65), p<.001 and 
Avoiders (M=75.29, SE=1.44), p=.01. There was no significant difference between Refusers and 
Avoiders. Applying non-parametric testing to the distributions of age scores also resulted in a 
significant difference between groups, χ2(2)=38.43, p<.001. Post hoc analysis pointed to 
significant differences in age between Participators (mean rank = 182.32) and Refusers (mean 
rank = 259.61) (p<.001), and Participators and Avoiders (mean rank = 253.99) (p=.003), but not 
between Refusers and Avoiders.  
There was no difference in gender across groups. A comparison of African American and 
white individuals resulted in no significant differences across groups (p=.42). Educational 
attainment did differ across AI interest groups, χ2 (4, N=449) = 11.42, p=.02. An examination of 
aggregated education groups revealed that more individuals who had completed graduate 
work/graduate degrees participated in amyloid imaging (38.4%), than refused (25.4%) or 
avoided (28.6%) amyloid imaging. Refusers, Avoiders, and Participators were comprised of 
similar percentages of individuals with some college or Associate’s or Bachelor’s degrees 
(35.9%, 38.1%, and 36.4%, respectively). Individuals who completed less than high school, a 
high school diploma, or GED were comprised of more Avoiders (38.8%) and Refusers (33.3%) 
than Participators (25.3%).  
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ADRC diagnostic group (normal, mild cognitive impairment, dementia) also differed 
significantly across amyloid interest groups, χ2 (4, N=449) = 30.448, p<.001. More Refusers 
(69.9%) were individuals with dementia, although they also comprised a majority of Avoiders 
(57.1%) and were less dominant among Participators (45.5%).  A greater percentage of 
individuals with MCI were Participators (33.3%) than Refusers (15.8%) or Avoiders (14.3%). 
Individuals with no cognitive impairment comprised more Avoiders (28.6%) than Participators 
(21.2%) or Refusers (14.4%). A significant difference was also noted among those experiencing 
a change in diagnosis, χ2 (2, N=449) = 20.023, p<.001. Participators had a greater percentage of 
individuals who experienced a diagnostic change (23.7%) than Refusers (7.7%) or Avoiders 
(16.7%). 
MMSE scores significantly differed across groups, F(2, 446)=12.317, p <.001, η2=.052. 
Participators (M=25.33, SE=.34) had significantly higher scores than Refusers (M=22.98, 
SE=.33), p<.001. There were no other significant differences in MMSE scores among amyloid 
imaging interest groups when comparing Participators to Avoiders (M=24.26, SE=.74), p=.420, 
or Refusers to Avoiders, p=.286. Non-parametric testing, completed due to normality violations, 
supported ANOVA findings. The distributions of MMSE scores were significantly different 
between groups, χ2(2)=24.61, p<.001. Post hoc analysis also revealed significant differences in 
MMSE scores between Participators (mean rank = 255.24) and Refusers (mean rank=193.08) 
(p<.001), but not Participators and Avoiders, or Refusers and Avoiders.  
There was additionally a significant difference in the age memory decline began across 
AI interest groups, F(2, 355)=12.855, p <.001, η2=.068. Participators (M=65.91, SE=.77) were 
significantly younger than Refusers (M=71.15, SE=.71) when memory decline was first noticed, 
p<.001). There were no other significant differences in age at onset among interest groups when 
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comparing Participators to Avoiders (M=70.07, SE=1.72), p=.089, or Refusers to Avoiders, 
p=.845. In non-parametric testing, the distributions of age at onset were significantly different 
between groups, χ2(2)=26.37, p<.001. Pairwise comparisons were again performed, revealing 
significant differences between Participators (mean rank = 146.91) and Refusers (mean rank = 
205.23) (p<.001), but, as before, no significant differences between Participators and Avoiders, 
or Refusers and Avoiders.  
Percentage of individuals with a psychiatric diagnosis was similar across amyloid interest 
groups and comprised approximately one-third of each group. Presence of comorbidity did 
significantly differ across AI groups, χ2 (2, N=448) = 6.890, p=.032. Participators had a greater 
percentage of individuals with no comorbidity (79.8%) than Refusers (68.8%) or Avoiders 
(69.0%). Finally, having a first degree relative with dementia did not differ across AI interest 
groups, χ2 (2, N=448) = 2.488, p=.288. Approximately half of each AI group was comprised of 
individuals with a dementia family history. 
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Table 10. Bivariate comparisons of Refusers, Avoiders, and Participators for the full sample 
Notes: ADRC: Alzheimer Disease Research Center; CCI: Charlson Comorbidity Index;  
MCI: Mild cognitive impairment; MMSE: Mini Mental State Exam; SE: Standard error 
 
 
  Refusers Avoiders Participators 
Independent Variables (n=209) (n=42) (n=198) 
Demographics 
       Age, Mean (Standard Error) 75.34 (.65) 75.29 (1.44) 69.88 (.66) 
     F(2, 446)=18.794, p <.001, η2=.078 
   Sex, n (%) 
        Female 121 (57.9) 23 (54.8) 97 (49.0) 
     Male 88 (42.1) 19 (45.2) 101 (51.1) 
     χ2 (2, N=449)=3.27, p=.20 
   Race, n (%) 
        African American 15 (7.2) 5 (12.5) 13 (6.7) 
     White 194 (92.8) 35 (87.5) 180 (93.3) 
     Fisher's Exact Test, p=.42, n=442 
  Education, n (%) 
        Less than HS/HS or GED 81 (38.8) 14 (33.3) 50 (25.3) 
     Some college/Associate's degree/Bachelor's degree 75 (35.9) 16 (38.1) 72 (36.4) 
     Graduate work/Graduate degree 53 (25.4) 12 (28.6) 76 (38.4) 
     χ2 (4, N=449)=11.42, p=.02 
   Cognition 
         ADRC diagnosis, n (%)    
     Normal 30 (14.4) 12 (28.6) 42 (21.2) 
     MCI 22 (15.8) 6 (14.3) 66 (33.3) 
     Dementia 146 (69.9) 24 (57.1) 90 (45.5) 
     χ2 (4, N=449)=30.45, p<.001 
    Change in ADRC diagnosis, n (%) 16 (7.7) 7 (16.7) 47 (23.7) 
     χ2 (2, N=449)=20.02, p<.001 
    MMSE score, Mean (SE) 22.98 (.33) 24.26 (.74) 25.33 (.34) 
      F(2, 446)=12.317, p <.001, η2=.052 
    Age at onset of memory symptoms, Mean (SE) 71.15 (.71) 70.07 (1.72) 65.91 (.77) 
      F(2, 355)=12.855, p <.001, η2=.068 
   Health 
        Psychiatric diagnosis, n (%) 68 (32.5) 15 (35.7) 59 (29.8) 
     χ2 (2, N=449)=.71, p=.70 
   Modified CCI score, n (%) 
        0 143 (68.8) 29 (69.0) 158 (79.8) 
     1+ 65 (31.3) 13 (31.0) 40 (20.2) 
     χ2 (2, N=448)=6.89, p=.03 
    Family History 
        Dementia family history, n (%) 104 (49.8) 20 (48.8) 113 (57.1) 
     χ2 (2, N=448)=2.49, p=.29 
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Bivariate comparisons of Participators and Non-Participators 
Overall, findings for bivariate comparisons of Participators and Non-Participators were 
similar to the above three-group differences. Table 11 presents these findings. Age significantly 
differed between groups, t(401.53)=6.065, p <.001. Participators were significantly younger than 
Non-Participators (M=69.88, SD=0.70; M=75.33, SD=.56, respectively). When comparing 
distributions using non-parametric tests to account for normality violations, Participators (mean 
rank = 182.32) were again significantly younger than Non-Participators (mean rank = 258.67), U 
= 16,398, z = -6.19, p < .001.  
Participators and Non-Participators were roughly equal in percentages of males and 
females with no significant difference noted, χ2 (1, N=449) = 3.126, p=.086. There was also no 
significant difference in AI participation groups between African Americans and whites, χ2 (1, 
N=449) = 0.264, p=.716.  
Educational attainment significantly differed between AI participation groups, χ2 (2, 
N=449) = 10.935, p=.004. Individuals with some college, Associate’s, or a Bachelor’s degree 
were roughly equal in percentages between Participators (36.3%) and Non-Participators (36.4%), 
yet Non-Participators had a greater percentage of individuals who completed less than high 
school, high school, or a GED than Participators (37.8% vs 25.9%). Inversely, Participators had a 
greater percentage individuals completing graduate work or a graduate degree than Non-
Participators (38.4% vs. 25.9%).  
ADRC diagnosis significantly differed between Participators and Non-Participators, χ2 
(1, N=449) = 17.865, p<.001. Participators were comprised of larger percentages of individuals 
with no cognitive impairment or MCI than Non-Participators (21.2% vs 16.7% and 33.3% vs. 
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15.5%, respectively) and a smaller percentage of IWDs (45.5% vs 67.7%). Change in diagnosis 
also significantly differed between groups, χ2 (2, N=449) = 25.660, p<.001, with Participators 
comprised of a greater percentage of individuals with a diagnostic change than Non-Participators 
(23.7% vs. 9.2%).  
A significant difference in MMSE score between groups provided an additional signal 
that Participators were less impaired that Non-Participators, t(444.777) = -4.789, p <.001. Non-
parametric testing also pointed to a significant difference in score distributions. MMSE scores 
for Participators (mean rank = 256.24) were significantly higher than for Non-Participators 
(mean rank = 200.36), U = 31,034, z = 4.55, p <.001. Mean MMSE score was 25.33 (SE=0.32) 
for Participators and two points lower for Non-Participators (M=23.20; SE=0.32), falling in the 
mild dementia range.  
Subjective report of age at onset of cognitive symptoms also differed between groups, 
t(304.302)=-4.966, p <.001. Participators were on the cusp of older adulthood when symptoms 
were first noted (M=65.91, SE=0.81), while Non-Participators were on average five years older 
(M=70.99, SE=0.63). Findings from non-parametric testing supported t-test findings; age at 
onset of cognitive decline occurred at a significantly younger age for Participators (mean rank = 
146.91) than for Non-Participators (mean rank = 203.28), U = 10,707, z = -5.09, p <.001.  
As with comparing the three amyloid interest groups, there was no difference between 
Participators and Non-Participators in psychiatric diagnosis, χ2 (1, N=449) = .547, p=.476. 
Approximately one-third of both Participators and Non-Participators received a psychiatric 
diagnosis (29.8% vs 33.1%, respectively). The modified CCI score again elicited a significant 
difference between groups, χ2 (1, N=448) = 6.888, p=.009. A greater percentage of Participators 
had an absence of physical health comorbidity (79.7%) than Non-Participators (68.8%). 
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Although Participators had a greater percentage of first-degree family members with dementia 
(57.1%) than Non-Participators (49.6%), the difference was not significant, χ2 (1, N=448) = 
2.475, p=.116.  
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Table 11. Bivariate comparisons of Participators and Non-Participators for the full sample  
  Non-Participators Participators 
Independent Variables (n=251) (n=198) 
Demographics 
  Age, Mean (SE) 75.33 (.56) 69.88 (0.70) 
      t(401.53)=6.065, p <.001 
  Sex, n (%) 
       Female 144 (57.4) 97 (49.0) 
     Male 107 (42.6) 101 (51.0) 
     χ2 (1, N=449)=3.126, p=.086 
  Race, n (%) 
       African American 20 (8.0) 13 (6.7) 
     White 229 (92.0) 180 (93.3) 
     χ2 (1, N=442)=0.264, p=.716 
  Education, n (%) 
       Less than HS/HS or GED 95 (37.8) 50 (25.9) 
     Some college/Associate's degree/Bachelor's degree 91 (36.3) 72 (36.4) 
     Graduate work/Graduate degree 65 (25.9) 76 (38.4) 
     χ2 (2, N=449)=10.935, p=.004 
  Cognition 
  ADRC diagnosis, n (%) 
       Dementia 170 (67.7) 90 (45.5) 
     Mild Cognitive Impairment 39 (15.5) 66 (33.3) 
     Normal 42 (16.7) 42 (21.2) 
     χ2 (1, N=449)=17.865, p<.001 
  Change in ADRC diagnosis, n (%) 23 (9.2) 47 (23.7) 
     χ2 (2, N=449)=25.660, p<.001 
  MMSE score, Mean (SE) 23.20 (0.32) 25.33 (0.31) 
      t(444.777)=-4.789, p <.001 
  Age at onset of cognitive symptoms, Mean (SE) 70.99 (0.63) 65.91 (0.81) 
         t(304.302)=-4.966, p <.001 
  Health 
  Psychiatric diagnosis, n (%) 83 (33.1) 59 (29.8) 
     χ2 (1, N=449)=.547, p=.476 
  CCI score, n (%) 
      0 172 (68.8) 158 (79.7) 
    1+ 78 (31.2) 40 (20.2) 
     χ2 (1, N=448)=6.888, p=.009 
  Family History 
  Dementia family history, n (%) 124 (49.6) 113 (57.1) 
     χ2 (1,N=448)=2.475, p=.116 
  Note: ADRC: Alzheimer Disease Research Center; CCI: Charlson Comorbidity Index;  
MMSE: Mini Mental State Exam; MCI: Mild cognitive impairment; SE: Standard error 
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4.3.2 Multivariate findings for the full sample 
Multinomial logistic regression for the full sample 
Overall, Model 1a, using Refusers as the referent group, was statistically significant, χ2 (22) = 
76.39, p<.001 and explained 19% (Nagelkerke R2) of the variance in amyloid imaging interest. 
Table 12 presents findings from Model 1a. Two of the nine variables included in the model had 
statistically significant associations. Age was significantly related to being a Participator or a 
Refuser, b=-0.05, χ2 (1) = 18.05, p<0.001. With each year of decreased age, the odds of being a 
Participator, compared to being a Refuser, increased by 5% (OR=0.95, 95% CI, 0.93-0.97). 
Whether a change in diagnosis occurred was also significantly related to being a Participator or a 
Refuser, b=-0.84, χ2 (1)=5.18, p=0.02. Individuals who had experienced no diagnostic transition 
were almost half as likely to be a Participator as a Refuser (OR=0.43, 95%, 0.21-0.89). No 
biopsychosocial factors were significantly associated with being an Avoider versus being a 
Refuser. 
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Table 12. Model 1a: Multinomial logistic regression of factors associated with interest in amyloid imaging, 
with ADRC diagnosis included in modeling (N=440) 
AI Interest 
Group   Estimate 
Std. 
Error Wald df p 
Odds 
Ratio 
95% Confidence 
Interval 
                
Lower 
Bound 
Upper 
Bound 
Avoider Intercept 0.38 1.93 0.04 1 0.845 
  
 
 
Age 0.00 0.02 0.00 1 0.955 1.00 0.96 1.04 
 
Sex, female -0.22 0.39 0.32 1 0.574 0.80 0.37 1.73 
 
Race, white -0.65 0.59 1.24 1 0.266 0.52 0.16 1.65 
 
Education, <HS/HS/GED (referent) 
       
 
 
Some college/Associate's/Bachelor's -0.10 0.49 0.05 1 0.833 0.90 0.34 2.37 
 
Graduate work/Graduate degree 0.15 0.43 0.12 1 0.726 1.16 0.50 2.67 
 
ADRC Diagnosis, Normal (referent) 
       
 
 
MCI -0.89 0.46 3.70 1 0.054 0.41 0.17 1.02 
 
Dementia -1.18 0.63 3.53 1 0.060 0.31 0.09 1.05 
 
Change in ADRC diagnosis, no -0.77 0.60 1.66 1 0.197 0.46 0.14 1.49 
 
Psychiatric diagnosis, no -0.38 0.39 0.98 1 0.324 0.68 0.32 1.45 
 
Modified CCI, 0 0.20 0.42 0.22 1 0.640 1.22 0.54 2.75 
 
Dementia family history, no 0.15 0.36 0.17 1 0.680 1.16 0.58 2.33 
Participator Intercept 4.36 1.18 13.64 1 0.000 
  
 
 
Age -0.05 0.01 18.05 1 0.000 0.95 0.93 0.97 
 
Sex, female -0.30 0.23 1.60 1 0.206 0.75 0.47 1.18 
 
Race, white -0.26 0.43 0.35 1 0.552 0.77 0.33 1.80 
 
Education, <HS/HS/GED (referent) 
       
 
 
Some college/Associate's/Bachelor's 0.40 0.29 1.94 1 0.164 1.50 0.85 2.65 
 
Graduate work/Graduate degree 0.28 0.27 1.05 1 0.305 1.32 0.78 2.23 
 
Diagnosis, Normal (referent) 
       
 
 
MCI -0.43 0.31 1.94 1 0.163 0.65 0.36 1.19 
 
Dementia 0.12 0.36 0.11 1 0.746 1.12 0.55 2.28 
 
Change in ADRC diagnosis, no -0.84 0.37 5.18 1 0.023 0.43 0.21 0.89 
 
Psychiatric diagnosis, no 0.25 0.24 1.01 1 0.316 1.28 0.79 2.06 
 
Modified CCI, 0 0.49 0.26 3.47 1 0.062 1.63 0.98 2.72 
  Dementia family history, no -0.26 0.22 1.41 1 0.235 0.77 0.50 1.18 
  Note: R2=.16 (Cox & Snell), .19 (Negelkerke). Model χ2(22)=76.39, p<.001.  
  HS=high school; GED=General Equivalency Diploma; ADRC=Alzheimer Disease Research Center;  
CCI=Charlson Comorbidity Index 
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Model 1b, with Refusers as the referent group and the cognition variable, ADRC 
diagnosis, replaced with MMSE score, is presented in Table 13. The logistic regression model 
was statistically significant, χ2(20)=75.20, p<.001, and again explained 19% (Nagelkerke R2) of 
the variance in amyloid imaging interest. Four of the nine variables included in the model had 
statistically significant associations. Age remained significantly associated with being a 
Participator or a Refuser, b=-0.05, χ2(1)=18.96, p<.001. With each year of decreased age, the 
odds of being a Participator, compared to a Refuser, increased by 5% (OR=0.95, 95% CI, 0.93-
0.97).  MMSE score was also significantly related to whether an individual participated in or 
refused amyloid imaging, b=0.07, χ2(1)=7.28, p=0.01. With each additional point increase in 
MMSE score, the odds of being a Participator, rather than a Refuser, increased by 7% (OR=1.07, 
95% CI, 1.02-1.12). Change in diagnosis continued to have a significant relationship with being 
a Participator versus a Refuser, b=-0.96, χ2(1)=8.47, p<.001. Those who had no change in 
diagnosis were one-third as likely to be a Participator compared to a Refuser (OR=.38, 95% CI, 
0.20-0.73). Lastly, presence of health comorbidities (measured by the modified Charlson 
Comorbidity Index) emerged as having a significant relationship to being a Participator 
compared to a Refuser, b=0.51, χ2(1)=3.86, p=.049. Participators were 1.7 times as likely as 
Refusers to have no comorbidities (OR = 1.67, 95% CI, 1.00-2.77). No psychosocial factors were 
significantly associated with being an Avoider versus being a Refuser. 
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Table 13. Model 1b. Multinomial logistic regression of factors associated with interest in amyloid imaging, 
with MMSE score included in modeling (N=440)  
 
 
 
 
 
 
 
AI Interest Group Estimate 
Std. 
Error Wald df p 
Odds 
Ratio 
95% Confidence 
Interval 
                
Lower 
Bound 
Upper 
Bound 
Avoider Intercept -2.01 2.18 0.85 1 0.356 
   
 
Age 0.00 0.02 0.03 1 0.861 1.00 0.96 1.04 
 
MMSE score 0.05 0.04 1.32 1 0.251 1.05 0.97 1.13 
 
Sex, female -0.13 0.39 0.11 1 0.742 0.88 0.41 1.88 
 
Race, white -0.67 0.58 1.34 1 0.247 0.51 0.16 1.59 
 
Education, <HS/HS/GED 
        
 
     Some college/Associate's/Bachelor's -0.06 0.50 0.01 1 0.904 0.94 0.36 2.49 
 
     Graduate work/Graduate degree 0.21 0.42 0.25 1 0.616 1.24 0.54 2.84 
 
Change in ADRC diagnosis, no -0.58 0.54 1.17 1 0.279 0.56 0.19 1.60 
 
Psychiatric Diagnosis, no -0.28 0.38 0.55 1 0.460 0.76 0.36 1.58 
 
Modified CCI, 0 0.30 0.41 0.52 1 0.469 1.35 0.60 3.03 
 
Dementia family history, no 0.16 0.36 0.21 1 0.649 1.18 0.59 2.36 
Participator Intercept 2.77 1.32 4.39 1 0.036 
   
 
Age -0.05 0.01 18.96 1 0.000 0.95 0.93 0.97 
 
MMSE score 0.07 0.03 7.28 1 0.007 1.07 1.02 1.12 
 
Sex, female -0.34 0.23 2.10 1 0.147 0.71 0.45 1.13 
 
Race, white -0.26 0.43 0.36 1 0.547 0.77 0.33 1.80 
 
Education, <HS/HS/GED 
        
 
     Some college/Associate's/Bachelor's 0.28 0.30 0.87 1 0.350 1.32 0.74 2.35 
 
     Graduate work/Graduate degree 0.20 0.27 0.55 1 0.459 1.22 0.72 2.08 
 
Change in ADRC diagnosis, no -0.96 0.33 8.47 1 0.004 0.38 0.20 0.73 
 
Psychiatric Diagnosis, no 0.23 0.24 0.93 1 0.336 1.26 0.79 2.03 
 
Modified CCI, 0 0.51 0.26 3.86 1 0.049 1.67 1.00 2.77 
  Dementia family history, no -0.21 0.22 0.94 1 0.332 0.81 0.53 1.24 
Note: R2=.16 (Cox & Snell), .19 (Negelkerke). Model χ2(20)=75.20, p<.001.  
      HS=high school; GED=General Equivalency Diploma; MMSE=Mini Mental State Exam; ADRC=Alzheimer Disease Research 
Center; CCI=Charlson Comorbidity Index 
 91 
Binary logistic regression for the full sample 
Refusers and Avoiders were combined to comprise the Non-Participators group (referent 
group) and compared to Participators. As in multinomial logistic regression and to account for 
the potential of multicollinearity between the cognition variables, ADRC diagnosis and MMSE 
score, two models were run, separating these variables. Model 2a includes ADRC diagnosis as 
an independent variable while Model 2b includes MMSE score as an independent variable.  
Model 2a was statistically significant, χ2 (11) = 66.45, p<.001 and explained 19% 
(Nagelkerke R2) of the variance in amyloid imaging participation (Table 14). Two of the eleven 
independent variables were statistically significant in modeling. Younger age was significantly 
related to whether individuals participated in amyloid imaging, b=-0.05, χ2 (1) = 19.97, p<0.001. 
With each year of decreased age, participation on amyloid imaging increased by 5% (OR=0.95, 
95% CI, 0.93-0.97). Change in cognition diagnosis was also significantly associated with 
amyloid imaging participation, b=0.67, χ2 (1) = 3.95, p=0.047. Individuals who had gone 
through a change in diagnosis were almost two times as likely to participate in amyloid imaging 
compared to those whose diagnosis remained the same, (OR=1.96; 95% CI, 1.01-3.80).  
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Table 14. Model 2a: Binary logistic regression of factors associated with participation in amyloid imaging, 
with ADRC diagnosis included in modeling (N=440) 
  Estimate 
Std. 
Error Wald df p 
Odds 
Ratio 
95% Confidence 
Interval 
  
      
Lower 
Bound 
Upper 
Bound 
Constant 3.19 0.90 12.68 1 .000 24.23     
Age  -0.05 0.01 19.96 1 .000 0.95 0.93 0.97 
Sex, female 0.26 0.22 1.30 1 .254 1.29 0.83 2.00 
Race, white 0.11 0.41 0.08 1 .779 1.12 0.50 2.49 
Education,  <HS/HS/GED (referent)   2.36 2 .307    Some college/Associate's/Bachelor's 0.25 0.26 0.92 1 .338 1.28 0.77 2.13 
Graduate work/Graduate degree 0.43 0.28 2.34 1 .126 1.53 0.89 2.66 
ADRC diagnosis, Normal (referent)   3.99 2 .136    MCI 0.36 0.34 1.14 1 .286 1.43 0.74 2.78 
Dementia -0.24 0.29 0.71 1 .400 0.79 0.45 1.38 
Change in ADRC diagnosis, no 0.67 0.34 3.95 1 .047 1.96 1.01 3.80 
Psychiatric diagnosis, no -0.31 0.23 1.76 1 .185 0.73 0.46 1.16 
Modified CCI, 0 -0.46 0.25 3.21 1 .073 0.63 0.39 1.04 
Dementia family history, no 0.28 0.21 1.80 1 .180 1.33 0.88 2.00 
Notes: R2=.14 (Cox & Snell), .19 (Negelkerke). Model χ2(11)=66.45, p<.001.  
HS=high school; GED=General Equivalency Diploma; ADRC=Alzheimer Disease Research Center; MCI=mild 
cognitive impairment; CCI=Charlson Comorbidity Index 
 
 
 
Model 2b, which includes MMSE score as an independent variable, was statistically 
significant, χ2 (11) = 68.84, p<.001 and explained 39% (Nagelkerke R2) of the variance in 
amyloid imaging participation (Table 15). Three of the eleven biopsychosocial factors were 
statistically significant in modeling. Age remained significantly associated to whether 
individuals participated in amyloid imaging, b=-0.05, χ2 (1) = 21.21, p<0.001. With each year of 
decreased age, participation in amyloid imaging increased by 5% (OR=0.95, 95% CI, 0.93-0.97). 
Higher MMSE score was significantly associated with amyloid imaging participation, b=0.06, χ2 
(1) = 6.18, p=0.013. As MMSE score increased by one, the odds of participating in amyloid 
imaging increased by 6% (OR=1.06, 95% CI 1.01-1.11). Experiencing a diagnostic change was 
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also significantly related to amyloid imaging participation, b=.83, χ2 (1) = 7.65, p=0.006. 
Individuals who underwent a diagnostic transition were more than twice as likely to participate 
in amyloid imaging, than not participate (OR=2.30, 95% CI, 1.28-4.16).  
 
 
 
Table 15. Model 2b: Binary logistic regression of factors associated with participation in amyloid imaging, 
with MMSE included in modeling (n=440) 
  Estimate 
Std. 
Error Wald df p 
Odds 
Ratio 
95% Confidence 
Interval 
       
Lower 
Bound 
Upper 
Bound 
Constant 1.816 1.080 2.827 1 .093 6.145     
Age  -.053 .012 21.211 1 .000 .948 .927 .970 
Sex, female .315 .223 1.991 1 .158 1.370 .885 2.122 
Race, white .112 .407 .076 1 .783 1.119 .503 2.486 
Education,  <HS/HS/GED (referent)   1.031 2 .597         Some college/Associate's/Bachelor's .160 .261 .377 1 .539 1.174 .704 1.957 
     Graduate work/Graduate degree .288 .284 1.028 1 .311 1.334 .764 2.330 
MMSE Score .060 .024 6.180 1 .013 1.062 1.013 1.113 
Change in ADRC diagnosis, no .834 .302 7.647 1 .006 2.303 1.275 4.159 
Psychiatric diagnosis, no -.282 .232 1.479 1 .224 .754 .479 1.188 
Modified CCI, 0 -.458 .251 3.315 1 .069 .633 .387 1.036 
Dementia family history, no .243 .211 1.321 1 .250 1.274 .843 1.927 
Notes: R2=.29 (Cox & Snell), .39 (Negelkerke). Model χ2(10)=68.84, p<.001.  
    HS=high school; GED=General Equivalency Diploma; MMSE=Mini Mental State Exam; ADRC=Alzheimer 
Disease Research Center; CCI=Charlson Comorbidity Index 
 
 
 
4.3.3 Summary of findings for full sample 
In bivariate analysis, being younger, having more education, less cognitive impairment 
(according to both ADRC diagnosis and MMSE score), experiencing a change in diagnosis, a 
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younger age at onset of cognitive symptoms, and no physical comorbidity were all significantly 
associated with greater interest in amyloid imaging participation, when compared to refusing any 
contact regarding AI (Refusers) or eventual refusal of AI participation (Avoiders). The same 
findings held when comparing AI Participators to AI Non-Participators. Participators were 
significantly younger, had more education, less cognitive impairment, experienced diagnostic 
transition, were younger at age of onset, and had no physical health comorbidities.  
In multinomial logistic regression, younger age, better MMSE score, and the occurrence 
of a cognition-related diagnostic transition were significantly associated with being a 
Participator, compared to a Refuser. An absence of physical health comorbidities only emerged 
as having a significant association with being a Participator in modeling that included MMSE 
score as a measure of cognition. There were no significant associations with being a Refuser in 
comparison to an Avoider. Binary logistic regression, comparing Participators to Non-
Participators, produced similar findings, with younger age, better MMSE score, and diagnostic 
transition significantly related to participation in amyloid imaging.  
4.4 BIOPSYCHOSOCIAL FACTORS ASSOCIATED WITH AMYLOID IMAGING 
INTEREST AND PARTICIPATION FOR THE SUBSAMPLE OF  
INDIVIDUALS WITH DEMENTIA 
This section addresses the research aim of examining biopsychosocial factors that are associated 
with of interest in and participation in amyloid imaging among a subsample of individuals with 
dementia. As with the full sample, results of bivariate analyses are first described, comparing 
differences in AI interest groups (Refusers, Avoiders and Participators) for each psychosocial 
 95 
variable. Next, bivariate findings comparing Participators to Non-Participators (Refusers and 
Avoiders) are presented. The results of four logistic regression models are presented. The first 
model (Model 3) applies multinomial logistic regression to examine factors associated with the 
three amyloid interest groups, with Refusers serving as the referent group. A binomial logistic 
regression model follows (Model 4), which again compare Participators to Non-Participators 
(referent group).  
This subsample was also limited to African Americans and whites, excluding 1 individual 
who was Asian and 3 individuals who were Multiracial. Additionally one case (a Refuser) was 
missing data for dementia family history and a second case was missing comorbidity data, 
limiting multivariate analysis to N=260.  
4.4.1 Bivariate findings for the subsample of individuals with dementia 
Bivariate comparisons of Refusers, Avoiders, and Participators  
The following table (Table 16) presents findings comparing three amyloid interest groups 
with each psychosocial variable under investigation. There were significant differences across 
groups for age, F(2, 256)=9.836, p <.001, η2=.071. Participators (M = 71.17, SE = 1.02) were 
significantly younger than both Refusers (M = 76.89, SE = 0.79), p<.001, but not Avoiders (M = 
75.29, SE = 1.44). There was no significant difference in age between Refusers and Avoiders. 
Addressing normality violations, the distributions of age were also significantly different 
between groups, χ2 (2) = 19.78, p<.001. Post hoc analysis also revealed significant differences in 
age between Participators (mean rank = 102.87) and Refusers (mean rank = 147.65) (p<.001), 
but no significant differences between Participators and Avoiders, or Refusers and Avoiders.  
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Percentages of males and females were not significantly different across amyloid interest 
groups, χ2 (2, 260) = 1.190, p=.552, and comprised approximately half of each group. There 
were no differences in percentages of African Americans and whites across amyloid interest 
groups (p=0.718). Due to small numbers of African Americans individuals within the sample, 
the majority were whites across groups. No significant differences in the three-category group of 
educational attainment were found across amyloid interest groups, χ2 (4, N=260) = 2.852, 
p=.589.  
MMSE scores did not significantly differ across groups, F(2, 256)=1.499, p=.225, 
η2=.012, and all fell within the mild dementia range. Non-parametric testing resulted in the same 
finding; distributions of MMSE score did not significantly differ between groups, χ2 (2) = 2.33, 
p=.312. Age at onset of cognitive symptoms significantly differed across interest groups, F(2, 
256)=7.947, p <.001, η2=.058. Post hoc comparisons revealed that Participators (M=66.97, 
SE=0.98) were significantly younger at age of onset than Refusers (M=71.87, SE=0.76), p<.001, 
while there were no differences between Participators and Avoiders (M=70.83, SE=1.88) or 
Refusers and Avoiders. In non-parametric testing, distributions of age at onset were again 
significantly different between groups, χ2 (2) = 14.44, p=.001. This post hoc analysis revealed 
significant differences in age between Participators (mean rank = 106.41) and Refusers (mean 
rank = 144.51), p<.001, but no significant differences between Participators and Avoiders, or 
Refusers and Avoiders.  
Psychiatric diagnosis did not significantly differ across amyloid imaging interest groups, 
χ2 (2, N=259) =0.789, p=.674. Individuals with a psychiatric diagnosis comprised 32.9% of 
Refusers, 41.7% of Avoiders, and 35.6% of Participators. Presence of comorbidities did 
significantly differ across amyloid interest groups, χ2 (2, N=260)=10.014, p=.007. Participators 
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(83.3%) had a larger percentage of individuals with no comorbidity, than Refusers (65.1%) or 
Avoiders (62.5%).  
Having at least one first degree relative with dementia did not differ across amyloid 
imaging interest groups, χ2 (2, N=259) =.101, p=.964. About half of each group was comprised 
of individuals with a family history. Care support relationship to the patient did significantly 
differ across AI interest groups, χ2 (4, N=260)=15.538, p=.004. Participators (74.4%) had a 
greater percentage of spousal or partner relationships (74.4%), than Refusers (49.3%) or 
Avoiders (62.5%). Refusers had greater a greater percentage of adult child (41.1%) or other care 
partners (9.6%) than Avoiders (33.3%; 4.2%) or Participators (23.3%; 2.2%).  
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Table 16. Bivariate comparisons of Refusers, Avoiders, and Participators for the subsample of individuals 
with dementia (N=260) 
  Refuser Avoider Participator 
Independent Variables (n=146) (n=24) (n=90) 
Demographics 
       Age, Mean (SE) 76.89 (.79) 75.29 (1.44) 71.17 (1.02) 
      F(2, 256)=9.836, p <.001, η2=.071 
   Sex, n (%) 
        Female 82 (56.2) 11 (45.8) 46 (51.1) 
     Male 64 (43.8) 13 (54.2) 44 (48.9) 
     χ2 (2, 260)=1.190, p=.552 
   Race, n (%) 
        African American 9 (6.2) 2 (8.7) 4 (4.6) 
     White 137 (93.8) 21 (91.3) 83 (95.4) 
     Fisher's Exact Test, p=.718 
   Education, n (%) 
        Less than HS/HS or GED 63 (43.2) 12 (50.0) 33 (36.7) 
     Some college/Associate's degree/Bachelor's degree 51 (34.9) 9 (37.5) 33 (36.7) 
     Graduate work/Graduate degree 32 (21.9) 3 (12.5) 23 (26.7) 
     χ2 (4, N=260)=2.852, p=.589 
   Cognition 
        MMSE Score, Mean (SE) 21.06 (.37) 20.88 (.92) 22.05 (.48) 
      F(2, 256)=1.499, p=.225, η2=.012 
    Age at Onset of Memory Symptoms, Mean (SE) 71.87 (.76) 70.83 (1.88) 66.97 (.98) 
      F(2, 256)=7.947, p <.001, η2=.058 
   Health 
        Psychiatric diagnosis, n (%) 48 (32.9) 10 (41.7) 32 (35.6) 
     χ2 (2, N=259)=.789, p=.674 
   Modified CCI Score, n (%) 
       0 95 (65.1) 15 (62.5) 75 (83.3) 
    1+ 51 (34.9) 9 (37.5) 15 (16.7) 
     χ2 (2, N=260)=10.014, p=.007 
   Family History 
        Dementia family history, n (%) 75 (51.4) 11 (47.8) 46 (51.1) 
     χ2 (2, N=259)=.101, p=.964 
   Care Support 
        Informant Relationship to Patient, n (%) 
        Spouse/partner 72 (49.3) 15 (62.5) 67 (74.4) 
     Child 60 (41.1) 8 (33.3) 21 (23.3) 
     Other 14 (9.6) 1 (4.2) 2 (2.2) 
     χ2 (4, N=260)=15.538, p=.004       
Notes: CCI: Charlson Comorbidity Index; MCI: Mild cognitive impairment;  
MMSE: Mini Mental State Exam; SE: Standard error 
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Bivariate comparisons of Participators and Non-Participators  
Table 17 presents findings comparing Participators and Non-Participators for the 
subsample of IWDs. Age was again significantly different between Participators and Non-
Participators, t(153.57)=4.059, p <.001. Participators were on average five years younger than 
Non-Participators (M=71.23, SE=1.14; M=76.62, SE=0.68, respectively). Non-parametric testing 
resulted in the same finding, U = 5,163, z = -4.31, p < .001.  
No differences were found between groups by sex, χ2 (1, 260) = .306, p=.603. Females 
comprised 51.1% of Participators and 54.7% of Non-Participators. The same was true when 
comparing African Americans with whites, p=.780. Due to low numbers of African Americans in 
the sample, the majority of both Participators and Non-Participators were white (95.4% and 
93.5%, respectively).  
Educational attainment did not significantly differ between Participators and Non-
Participators, χ2 (2, N=260) = 1.776, p=.412. Individuals who completed less than high school, a 
high school diploma, or GED comprised a greater percentage of Non-Participators (44.1%) than 
Participators (36.7%). Those with some college or an Associate’s or Bachelor’s degree had fairly 
similar percentages represented among Participators (36.7%) and Non-Participators (35.3%). 
Individuals who completed graduate work or a graduate degree comprised a larger percentage of 
Participators (26.7%) than Non-Participators (20.6%).   
Mini Mental State Exam scores were not significantly different between groups, t(258)=-
1.77, p =.078. Mean scores were in the mild dementia range for both Participators (M=22.07, 
SE=0.44) and Non-Participators (M=21.04, SE=0.35). The same non-significant finding was 
derived from non-parametric testing, U=8.519, z=1.51, p=.13. Age at onset of cognitive decline 
did significantly differ between amyloid imaging participation groups, t(156.34)=3.67, p <.001. 
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Non-parametric testing resulted in the same finding, U = 5,482, z = -3.76, p < .001. Participators 
were significantly younger at age of onset (M=67.07, SE=1.08) than Non-Participators (M = 
71.72, SE = 0.66). 
Presence of a psychiatric diagnosis did not differ between amyloid imaging participation 
groups, χ2 (2, N=259) = 0.79, p=.674. About one-third of both Participators and Non-
Participators were comprised of individuals with a psychiatric diagnosis (35.6% and 34.1%, 
respectively). Presence of physical health comorbidity significantly differed between groups, χ2 
(1, N=260) = 9.95, p=.002. Participators had a lower percentage of individuals with comorbidity 
(16.7%) than Non-Participators (35.3%).  
There was no significant difference between amyloid imaging participation groups in 
whether individuals had a first degree relative with dementia, χ2 (1, N=259)=.001, p=.973. 
About half of each group was comprised of individuals with a dementia family history 
(Participators, 51.1%; Non-Participators, 50.9%). 
Care support relationship significantly differed between AI participation groups, p=.001. 
Spousal or partner relationships comprised a greater percentage of Participators (74.4%) than 
Non-Participators, while adult child and other care partner relationships accounted for greater 
percentages of Non-Participators (40.0% and 8.8%) than Participators (23.3% and 2.2%). 
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Table 17. Bivariate comparisons of Participators and Non-Participators for the subsample of individuals 
with dementia (N=260) 
  Non-Participator Participator 
Independent Variables (n=170) (n=90) 
Demographics 
  Age, Mean (Standard Error) 76.62 (0.68) 71.23 (1.14) 
      U = 5,163, z = -4.31, p < .001 
  Sex, n (%) 
       Female 93 (54.7) 46 (51.1) 
     Male 77 (45.3) 44 (48.9) 
     χ2 (1, 260)=.306, p=.603 
  Race, n (%) 
       African American 11 (6.5) 4 (4.6) 
     White 158 (93.5) 83 (95.4) 
     Fisher's Exact Test, p=.780 
  Education, n (%) 
       Less than HS/HS or GED 75 (44.1) 33 (36.7) 
     Some college/Associate's degree/Bachelor's degree 60 (35.3) 33 (36.7) 
     Graduate work/Graduate degree 35 (20.6) 24 (26.7) 
     χ2 (2, N=260)=1.776, p=.412 
  Cognition 
  MMSE Score (with WORLD), Mean (SE) 21.04 (0.35) 22.07 (0.44) 
      U = 8,519, z = 1.51, p = .13 
  Age at Onset of Memory Symptoms, Mean (SE) 71.72 (0.66) 67.07 (1.08) 
      U = 5,482, z = -3.76, p < .001 
  Health 
  Psychiatric diagnosis, n (%) 58 (34.1) 32 (35.6) 
     χ2 (2, N=259)=.789, p=.674 
  Modified Charlson Comorbidity Score, n (%) 
      0 110 (64.7) 75 (83.3) 
    1+ 60 (35.3) 15 (16.7) 
     χ2 (1, N=260)=9.948, p=.002 
  Family History 
  Dementia family history, n (%) 86 (50.9) 46 (51.1) 
     χ2 (1, N=259)=.001, p=.973 
  Care Support 
  Informant Relationship to Patient, n (%) 
       Spouse/partner 87 (51.2) 67 (74.4) 
     Child 68 (40.0) 21 (23.3) 
     Other 15 (8.8) 2 (2.2) 
     χ2 (1, N=260)=14.076, p<.001     
Notes: CCI: Charlson Comorbidity Index; MCI: Mild cognitive impairment;  
MMSE: Mini Mental State Exam; SE: Standard error 
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4.4.2 Multivariate findings for the subsample of individuals with dementia 
Multinomial logistic regression for the subsample of individuals with dementia 
The multinomial logistic regression model (Model 3, See Table 18), comparing Participators and 
Avoiders to the referent group, Refusers, was statistically significant, χ2(24)=48.01, p=.003, and 
explained 21% (Nagelkerke R2) of the variance in amyloid imaging interest. Presence of 
comorbidity was significantly associated with being a Participator compared to a Refuser, b=-
1.05, χ2(1)=7.91, p=0.005.  Individuals with no comorbidity were almost three times more likely 
to be a Participator, than a Refuser (OR=2.85, 95% CI, 1.37-5.90). Care support relationship to 
the patient was an additional factor distinguishing Participators from Refusers. Having a spouse 
or partner in a care support role rather than an adult child or another type of care partner 
significantly related to participation in amyloid imaging, compared to refusal to any contact 
regarding imaging (b=-0.76, χ2(1)=4.03, p=0.045 and  b=-2.25, χ2(1)=7.62, p=0.006, 
respectively). Individuals with an adult child providing care support were half as likely to be a 
Participator than a Refuser (OR=.47, 95% CI, 0.22-0.98), while individuals with care support 
other than a spouse/partner or adult child were one-tenth as likely to be a Participator than a 
Refuser (OR=0.11, 95% CI, 0.02-0.52). No other psychosocial variables differentiated Predictors 
from Refusers. Additionally, no factors significantly distinguished Avoiders from Refusers.  
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Table 18. Model 3: Multinomial logistic regression of factors associated with participation in amyloid 
imaging for the subsample of individuals with dementia (N=255) 
AI Interest 
Group   Estimate 
Std. 
Error Wald df p 
Odds 
Ratio 
95% Confidence 
Interval 
                
Lower 
Bound 
Upper 
Bound 
Avoider Constant 1.12 2.52 0.20 1 0.657 
  
 
 
Age  -0.08 0.08 0.91 1 0.341 0.93 0.79 1.08 
 
MMSE score 0.00 0.05 0.00 1 0.993 1.00 0.90 1.11 
 
Age at onset of cognitive decline 0.06 0.08 0.57 1 0.449 1.06 0.91 1.24 
 
Sex, female 0.50 0.55 0.84 1 0.361 0.61 0.21 1.77 
 
Race, white 0.97 0.90 1.17 1 0.279 0.38 0.07 2.20 
 
Education,  Less than HS/HS/GED 
(referent) 
       
 
 
     Some college/Associate's/Bachelor's -0.05 0.51 0.01 1 0.916 0.95 0.35 2.59 
 
     Graduate work/Graduate degree -1.34 0.83 2.59 1 0.108 0.26 0.05 1.34 
 
Age at onset of cognitive decline 0.06 0.08 0.57 1 0.449 1.06 0.91 1.24 
 
Psychiatric diagnosis, no 0.59 0.49 1.44 1 0.231 0.56 0.21 1.45 
 
Modified CCI, 0 -0.29 0.53 0.29 1 0.591 1.33 0.47 3.80 
 
Dementia family history, no -0.23 0.48 0.23 1 0.635 1.25 0.49 3.19 
 
Care Support Relationship, Spouse/partner (referent) 
      
 
 
     Adult child -0.12 0.59 0.04 1 0.837 0.89 0.28 2.83 
 
     Other -1.36 1.14 1.43 1 0.232 0.26 0.03 2.39 
Participator Constant 1.81 1.64 1.22 1 0.270 
  
 
 
Age  -0.05 0.05 1.12 1 0.289 0.95 0.86 1.05 
 
MMSE score 0.06 0.04 2.86 1 0.091 1.06 0.99 1.14 
 
Age at onset of cognitive decline 0.01 0.05 0.02 1 0.903 1.01 0.91 1.11 
 
Sex, female -0.08 0.34 0.06 1 0.809 1.09 0.56 2.10 
 
Race, white 0.56 0.68 0.66 1 0.415 0.57 0.15 2.19 
 
Education,  Less than HS/HS/GED 
(referent) 
       
 
 
     Some college/Associate's/Bachelor's -0.05 0.35 0.02 1 0.890 0.95 0.48 1.91 
 
     Graduate work/Graduate degree -0.08 0.40 0.04 1 0.849 0.93 0.42 2.03 
 
Psychiatric diagnosis, no 0.01 0.32 0.00 1 0.983 0.99 0.53 1.86 
 
Modified CCI, 0 -1.05 0.37 7.91 1 0.005 2.85 1.37 5.90 
 
Dementia family history, no -0.06 0.30 0.03 1 0.856 1.06 0.59 1.90 
 
Care Support Relationship, Spouse/partner (referent)  
 
 
     Adult child -0.76 0.38 4.03 1 0.045 0.47 0.22 0.98 
       Other -2.25 0.82 7.62 1 0.006 0.11 0.02 0.52 
Note: R2=.17 (Cox & Snell), .21 (Negelkerke). Model χ2(24)=48.01, p=.003.  
    
 
HS=high school; GED=General Equivalency Diploma; MMSE=Mini Mental State Exam; CCI=Charlson 
Comorbidity Index 
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Binomial logistic regression for the subsample of individuals with dementia 
The final binomial logistic regression model (Model 4, See Table 19) comparing 
Participators to Non-Participators (referent group) was also statistically significant, 
χ2(12)=39.39, p<.001, and explained 20% (Nagelkerke R2) of the variance in amyloid imaging 
participation. Presence of medical comorbidity significantly related to being a Participator 
compared to a Non-Participator, b=-1.01, χ2 (1)=7.65, p=0.006. Having no comorbidity meant 
individuals were more than two and a half times more likely to participate in amyloid imaging 
than not participate (OR=2.74, 95% CI 1.34-5.59).  As in multinomial modeling, care support 
relationship was significantly associated with participation in amyloid imaging when comparing 
adult child supports to spousal/partner or other supports (b=-.75, χ2(1)=4.06, p=0.009), or 
spousal/partner and adult child supports to other supports (b=-2.09, χ2(1)=6.72, p=0.010).  
Individuals with adult children care supports were half as likely to be Participators as individuals 
with spousal/partner or other care support relationships (OR=0.47, 95% CI, 0.23-0.98). 
Individuals with other care relationships were about one-tenth as likely to be Participators as 
individuals with spousal/partner or adult child relationships (OR=0.12, 95% CI, 0.03-0.60).  
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Table 19.Model 4: Binary logistic regression of factors associated with participation in amyloid imaging 
for the subsample of individuals with dementia (N=255)  
  Estimate 
Std. 
Error Wald df p 
Odds 
Ratio 
95% Confidence 
Interval 
              
Lower 
Bound 
Upper 
Bound 
Constant 1.17 1.58 0.55 1 0.459 3.22 
  Age  -0.04 0.05 0.76 1 0.385 0.96 0.87 1.06 
Sex, female -0.16 0.33 0.25 1 0.620 1.18 0.62 2.23 
Race, white 0.41 0.66 0.38 1 0.535 0.66 0.18 2.43 
Education,  <HS/HS/GED (referent) 
  
0.11 2 0.945 
        Some college/Associate's/Bachelor's -0.04 0.34 0.01 1 0.907 0.96 0.49 1.88 
     Graduate work/Graduate degree 0.09 0.39 0.05 1 0.820 1.09 0.51 2.35 
MMSE score 0.06 0.04 3.04 1 0.082 1.06 0.99 1.14 
Age at onset of cognitive decline 0.00 0.05 0.00 1 0.968 1.00 0.90 1.10 
Psychiatric diagnosis, no -0.09 0.31 0.08 1 0.780 1.09 0.59 2.01 
Modified CCI, 0 -1.01 0.36 7.65 1 0.006 2.74 1.34 5.59 
Dementia family history, no -0.02 0.29 0.01 1 0.943 1.02 0.58 1.81 
Care support relationship, Spouse/partner (referent) 
  
9.40 2 0.009 
       Adult child -0.75 0.37 4.06 1 0.044 0.47 0.23 0.98 
     Other -2.09 0.81 6.72 1 0.010 0.12 0.03 0.60 
Notes: R2=.14 (Cox & Snell), .20 (Negelkerke). Model χ2(12)=39.39, 
p<.001.  
     HS=high school; GED=General Equivalency Diploma; MMSE=Mini Mental State Exam; CCI=Charlson 
Comorbidity Index 
 
 
 
4.4.3 Summary of findings for the subsample with individuals with dementia 
In bivariate analysis, being younger, younger age at onset of cognitive symptoms, no physical 
comorbidity, and care support relationship were all significantly associated with greater interest 
in amyloid imaging participation, when compared to refusing any contact regarding AI or 
eventual refusal of AI participation. The same findings held when comparing AI Participators to 
AI Non-Participators.  
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In multivariate analysis, both in multinomial and binomial logistic regression modeling, 
biopsychosocial factors that were significantly associated with being a Participators were 
absence of comorbidity and a spousal/partner care support relationship. There were no factors 
that significantly distinguished Refusers from Avoiders.   
4.5 RESULTS SUMMARY 
In summary and for the full sample, significant factors associated with interest in amyloid 
imaging were younger age, better scoring on cognitive testing, and the experience of a change in 
cognition diagnosis. These findings held upon examination of biopsychosocial factors related to 
participation in AI. When examining the subset of IWDs, absence of comorbidity and having a 
spousal or partner care support relationship was significantly related to both interest and 
participation in AI. The following chapter will discuss these findings within the context of 
current research on participation in dementia screening, genetic testing and diagnostic 
assessment, as well as current work exploring engagement in dementia research studies.  
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5.0  DISCUSSION 
 
Early detection of Alzheimer’s disease (AD) allows patients and families extended time to care 
plan for the future and amyloid imaging (AI) is developing into a primary tool for gaining insight 
regarding cognitive status. This study aimed to identify the patients that are being included in 
these research advances and who may be missing out on participation in AI. Results from a 
sample of individuals who were followed at an Alzheimer Disease Center, and were queried 
regarding their willingness to participate in amyloid imaging studies, may also provide some first 
steps for social workers to understand what biopsychosocial factors may boost, or impede, 
participation in amyloid imaging research. To summarize, significant factors associated with 
interest in AI were younger age, scoring better on cognitive testing, and experiencing a change in 
cognitive diagnosis. The same findings resulted when examining factors related to AI research 
participation. Individuals with dementia were more likely to participate and express interest in 
amyloid imaging if they had no medical comorbidities and had spousal or partner care support. 
These findings lay the groundwork for understanding how AI may be adopted in clinical 
practice, and given the growing availability for testing that may detect AD pathology before 
symptoms arise, point to a clear need for clinicians to have discussions about dementia and 
dementia testing earlier in their care relationships. Limitations of the study and implications for 
practice and research are also discussed. 
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5.1 FACTORS ASSOCIATED WITH INTEREST AND PARTICIPATION IN 
AMYLOID IMAGING 
5.1.1  Experiencing cognitive diagnostic change 
Experiencing a change in cognition diagnosis from the Alzheimer Disease Research Center 
(ADRC) was significantly related to participation in amyloid imaging research, and this 
association held throughout modeling for the full sample. The presence of a change in diagnosis 
incorporated a range of diagnostic experiences, although all had the shared experience of 
meeting with a social worker and clinician to discuss the diagnosis and consider treatment and 
care plan options. Most individuals were told of a cognitive impairment diagnosis and a 
progression in illness process, whether it was a diagnosis of mild cognitive impairment (MCI) or 
dementia. In light of a diagnostic transition, individuals may feel that an uncertainty in diagnostic 
status exists, and AI participation provides an action that can be taken to address this uncertainty. 
Much has been written about the experience of diagnostic disclosure, either of mild 
cognitive impairment or dementia, predominantly within studies using qualitative methods 
(Bamford et al., 2004; Robinson et al., 2011). Reviews of work point to a wide characterization 
of experiences, with negative and positive consequences resulting from diagnostic disclosure, as 
well as high variability in beliefs and attitudes corresponding to the diagnostic revelation 
(Bamford et al., 2004). All of which points to the weighty, transformative nature of cognitive 
diagnosis. Beard (2004) identified diagnosis as a “defining moment” for patients with early AD 
or a hallmark in the illness trajectory, especially in the absence of any ability to change the 
treatment process. A follow-up study (Beard & Fox, 2008) of individuals with early-stage AD or 
MCI reported a strong patient interest in being proactive following a diagnosis and seeking 
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adjustments that would benefit well-being. One quantitative study found positive, AD-related 
health behavior change (e.g. taking medications, changes to diet or exercise) was a significant 
occurrence one year after the receipt of information regarding a positive AD genetic 
susceptibility status for individuals with an immediate family history of AD (Chao et al., 2008). 
This proactive post diagnosis behavior could certainly extend to amyloid testing where, as in the 
current sample, individuals receiving a cognitive impairment diagnosis positively view the 
pursuit of AI as a means to engage in meaningful activity that might result in a health benefit.  
Social workers play an especially pronounced role at this critical moment in the care 
continuum. All participants receiving a change in diagnosis had additional time with social work 
staff for discussion focused on understanding and processing diagnostic findings, care planning, 
and considering strategies to cope with and compensate for memory loss. Patient and family 
discussions with the social worker are weighty. They may focus on the how to support patient 
engagement in meaningful activity in the face of memory loss or balancing an increasing need 
for support with patient independence. Given the depth and magnitude of the discussion, there is 
no doubt that a therapeutic alliance is likely formed among discussion members - an enriched 
relationship between the patient, family, and clinicians. Equal partnerships within this alliance 
are considered to be the ideal, with a client-centered approach to care decision-making (Dupuis 
et al., 2012). While diagnostic experiences varying on the ideal were more likely, social work 
facilitation to attain a supportive, patient-centered, authentic relationship may have led patients 
and families to seek a continuing contact with the ADRC, via participation in AI. As social 
workers are also one of the first in-person contacts with memory clinic staff, a first source of 
information regarding AI studies, and an ongoing point of contact for the patient-family dyad, a 
natural link between social work and AI involvement occurs, and may facilitate AI participation.  
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5.1.2 Younger age and amyloid imaging 
For the full sample, younger age was significantly associated with AI interest and participation, 
notably when controlling for physical comorbidity and dementia status. As noted in the literature 
review, the same finding was reported in studies examining participation in AD genetic testing 
(Demirovic et al., 2003) and intent to participate in cognitive assessment (Boustani et al., 2006; 
Dale et al., 2008; Demirovic et al., 2003; Fowler et al., 2012).  
As this sample was predominantly comprised of older adults (3.4% were <55 years), it 
may be that the “young-old” have the greatest interest in testing. A multi-country study of 
interest in preclinical testing for Alzheimer’s disease reported that individuals who expressed 
high interest in testing were in the 50-64 and 65-74 age ranges, rather than older (75-85+ years) 
and younger (30-49 years) age groups (Wikler, Blendon, & Benson, 2013). It may be that the 
development of cognitive symptoms are believed to be closer at hand than for young adults, 
while the opportunity to change health behaviors and care plan may be viewed as more viable, 
with more potential for positive outcomes, than for their older counterparts. Previous work has 
also shown that the “old-old” have greater negative health behavior changes, compared to the 
“young-old” (Zanjani, Schaie, & Willis, 2006). 
Planning for the future may in fact be primarily on the minds of the “young-old,” 
particularly those seeking information about their cognitive status. Researchers examining the 
completion of advance directives in a sample derived from the same setting as for this 
dissertation reported that ADRC participants younger than age 65 were significantly more likely 
to have an advance directive in place than individuals age 65 and older (Garand, Dew, Lingler, & 
DeKosky, 2011). A survey using a representative sample of older adults (age 55+) in Allegheny 
County, Pennsylvania reported that from the age groups of 55-64 to 65-74, a large jump occurs 
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in the percentage of older adults that have a living will (34% to 58%) or health care power of 
attorney (35% to 60%; University Center for Social and Urban Research, 2014). “Local” 
percentages are similar to those based on a nationally representative mail panel survey (Rao, 
Anderson, Lin, & Laux, 2014), in which percentages of advance directive completion 
significantly differed between ages 35-54, 55-65, and ≥65 years, and increased with age groups 
(19.2%, 29.3%, and 51.2%, respectively). 
While the “young-old” may be those first seeking access to tools that may better delineate 
disease status, those who are older may in fact be getting left out. A systematic review of studies 
examining variations in medical care provision for individuals with dementia reported high 
variation in the use of diagnostic tools, including memory testing and imaging (Sivananthan, 
Puyat, & McGrail, 2013). A follow-up, population-based study examining variation in the 
application of dementia care guidelines in primary care practices reported that older age of 
patients with dementia were significantly associated with less adherence to guideline-consistent 
clinical care (Sivananthan, Lavergne, & McGrail, 2015). The authors attributed the difference to 
a lessened inclination among physicians to complete imaging when it may create a hardship for 
the patient. Older individuals may also perceive that cognitive impairment is an inevitability in 
older age (Ayalon & Areán, 2004), with little utility gained from pursuing confirmatory testing. 
Further exploration of these age differences, to tease out whether underlying motivations do in 
fact differ by age groups, is warranted. Additionally, from a clinical perspective, amyloid 
imaging counseling protocols may need to particularly address the concerns of the older-old 
regarding the potential hardships imposed by AI, and the potential value gained.    
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5.1.3 Better cognition associated with participation 
Although diagnostic status was not a factor associated with of amyloid imaging interest or 
participation in regression modeling, as hypothesized, a higher Mini Mental State Exam 
(MMSE) score did relate to both interest and participation. While this dissertation unfortunately 
was not able to examine the patient’s subjective perception of memory status, less impairment 
may imply greater patient decisional ability to make a determination regarding AI. And, when 
decisional impairment does exist, family members or decision-making proxies may be more 
hesitant to enroll the patient in something that may be difficult for the patient to understand or 
viewed as onerous. Studies examining the reasons that individuals do participate in dementia 
research often cite altruism as a key motivator (Jefferson et al., 2011); when another individual is 
making the decision, altruism may play a lessor role. Older adults queried about their views on 
surrogate decision-making for dementia studies using a range of protocols (e.g. lumbar puncture, 
vaccine, randomized controlled trial, gene-transfer neurosurgical study) reported that comfort 
with surrogate decision-making participation was not absolute (Kim et al., 2009). Therefore, the 
conservative route, in which AI participation is not pursued, may be more common when patient 
decisional ability is in question. 
5.1.4  Education was not associated with participation 
While educational attainment was initially significant in bivariate comparisons for the full 
sample as hypothesized, it did not remain significant in multivariate analysis. Education levels of 
the sample were higher than for individuals age 60 and over residing in the Pittsburgh 
Metropolitan Statistical Area (MSA; U.S. Census Bureau, 2014). This may mean that any self-
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selection bias related to education has already occurred when individuals elected to participate in 
a memory research clinic, and was washed out as a significant variable related to AI 
involvement; or a differing, non-significant relationship between education and AI participation 
may simply exist than that noted between education and dementia research participation. 
5.2 FACTORS ASSOCIATED WITH INTEREST AND PARTICIPATION IN 
AMYLOID IMAGING FOR INDIVIDUALS WITH DEMENTIA 
At the time of data collection when studies were being conducted using amyloid imaging, 
individuals with dementia (IWDs) were the focus of research. AI was most widely utilized by 
this group. There now are firmer recommendations regarding who should complete AI in the 
clinical setting (Johnson et al., 2013) and most work is focusing on the implementation of 
appropriate use criteria (AUC) that include early-onset, atypical, and mixed presentations of 
dementia as diagnoses of interest (Zakaid, 2015). However an examination of IWDs, separate 
from the full sample, does help tease out who participates given this constellation of symptoms 
and progression and findings are likely applicable to individuals with dementia, who also meet 
the AUC recommendations.  
5.2.1 Absence of medical comorbidity 
The relationship between health comorbidity and AI participation differed from what had been 
hypothesized. However, a previous study finding that comorbidity was related to interest in 
memory screening used a sample of community-dwelling older adults with varying subjective 
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report of memory problems (Boustani et al., 2003). The current, differing finding in this 
dissertation may be specific to IWDs for which ongoing health concerns, in addition to a 
dementia diagnosis, may already require significant health care use that is more highly 
prioritized over further diagnostic testing for dementia. As AI may not be viewed to lead to a 
change in treatment protocol or health status in comparison to the ongoing monitoring and 
treating of other chronic health conditions, its import may have less weight. Comorbidity in this 
sample was lower than that reported in a community-based sample of people with AD 
(Doraiswamy, Leon, Cummings, Marin, & Neumann, 2002). Alternatively, good physical health 
may also mean participants are more available and inclined to be active participants in their 
health. Good physical health may in turn imply no functional impairments that would make it 
difficult to complete imaging or create health-related concerns.  
Physical health problems, including associated medication regimens, may also impact 
cognition and neurodegeneration, possibly making it all the more important to better tease out 
the underlying condition causing cognitive impairment. Comorbid conditions commonly co-
occur with cognitive impairment and correlate with greater cognitive impairment (Doraiswamy 
et al., 2002). Additionally, appropriate use criteria recommends the use of AI in instances when 
individuals present with dementia of mixed etiology, including cerebrovascular disease or 
another medical condition (Johnson et al., 2013). Pre-test counseling protocols, not only tailored 
to diagnostic status, but also incorporating health history, may better reach those who could most 
benefit from amyloid imaging.  Compared to adults with no dementia diagnosis, IWDs  
experience more potentially avoidable hospitalizations due to complications related to comorbid 
conditions, predominantly diabetes and hypertension (Lin, Fillit, Cohen, & Neumann, 2013). 
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Focusing on these health conditions, in the context of a dementia diagnosis, is therefore critical 
and should take precedence.  
5.2.2 Spousal or partner care support 
Although individuals with dementia have an interest  in being involved in their care decisions 
(von Kutzleben, Schmid, Halek, Holle, & Bartholomeyczik, 2012), qualitative work has 
characterized varied modes of discussion occurring between IWDs, family members, and care 
managers to elicit care preferences, and noted that family preferences do play a pivotal role in 
determining care outcomes (Österholm, Taghizadeh Larsson, & Olaison, 2015). As hypothesized 
and supported by previous research (Cary et al., 2015), spousal and partner care support 
relationships significantly related to AI interest and participation. Greater time availability in 
retirement and more overall interest in meaningful activity for the person with dementia may be 
driving this relationship. Secondary data analysis using the National Alzheimer’s Coordinating 
Center Uniform Data Set (NACC UDS) found that participation in clinical trials was less 
common for patients with adult children as study partners than spousal study partners due to the 
patient’s age, poorer health, poor cognition and the inability of the adult child study partner to 
allocate time for clinical trial visits (Grill, Monsell, & Karlawish, 2012). Adult children 
experience greater role conflicts between caregiving and work that inhibit participation (Pinquart 
and Sorensen, 2007). Social work counseling protocols need to explore ways to support care 
dyads when care partner time limits related to work and family obligations inhibit participation. 
One option would be to identify additional sources of care support for the patient who may have 
an interest in facilitating AI involvement. Better employer support and greater societal 
acceptance of family leave programs might additionally free adult children to apply more time to 
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care roles and responsibilities. For care supports comprising the “other” group, further 
delineation of those care support relationships that comprise this group is needed. It may be that 
“secondary” relationships may result in a hesitancy to make decisions about AI participation and 
may signify a need for additional support in understanding the process and implications of AI. 
5.3 LIMITATIONS 
Several limitations are worth noting for this dissertation, primarily related to the study sample. 
First, it is important to reiterate that the individuals who completed amyloid imaging in this 
sample did not receive the results of testing. The key difference primarily relates to differing 
risks and benefits that arise when completing a clinical, versus a research, scan. Since a research 
scan does not conclude with disclosure of test results, the main risks relate to the amyloid 
imaging procedure, including exposure to a radioactive tracer and a lengthened time of 
immobility. In fact, one might view there to be less risk associated with a research scan than with 
a clinical scan.  In addition to procedural risks, a clinical scan results in findings placed in the 
patient’s medical record, and, although confidential, may be a potential source of discrimination 
related to employment, health insurance, or long-term care insurance. Currently there are no 
legal protections for the patient against such discrimination, however a federal law that prohibits 
health insurance and employment discrimination related to genetic information (The Genetic 
Information Nondiscrimination Act of 2008) provides a template for future legislation.  
Given the provision of results that come with a clinical scan, counseling regarding the 
risks and benefits would hypothetically occur in conjunction with imaging, and also address the 
interpretation of results, emotional response of the patient and family, and its impact on 
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treatment and health outcomes. One study examining interest in research results disclosure 
within a sample of cognitively normal individuals, who had participated in a longitudinal 
cognitive assessment study based in an Alzheimer Disease Center, reported significantly lower 
interest in disclosure following the receipt of an educational session numerating the risks and 
benefits related to receiving test results (Gooblar et al., 2015). Further examination of the same 
biopsychosocial factors within a similar substantially sized sample of individuals who have been 
approached regarding the completion of a clinical scan is certainly warranted. 
Second, a small number of Avoiders (9.4%, n=42), individuals who first expressed 
interest, yet never actually participated in AI was derived from the categorization process for AI 
interest groupings.  This may have limited the comparisons made between Avoiders and the 
other interest groups, Refusers and Participators. However, these groupings were derived from 
ten years of ADRC registry participation and provided a fairly accurate snapshot of the overall 
prevalence of AI interest and participation.  
Third, the sample was derived from a research-focused Alzheimer’s Disease Center, and 
may differ in motivation levels regarding dementia research participation and overall interest in 
cognitive assessment from the general population. The dissertation sample did, however, share 
some similarities with demographic reports from U.S. Census data for individuals age 60 and 
older residing in the Pittsburgh Metropolitan Statistical Area (MSA; U.S. Census Bureau, 2014). 
Median age was higher than that reported in Census data (75 years versus 70 years). However, 
similar percentages of males and females were evident when comparing the study sample to U.S. 
Census estimates (53.7% female/46.3% male versus 55.8% female/44.2% male, respectively). 
Racial composition was also similar, with the study sample comprised of slightly more African 
Americans than the Pittsburgh MSA (7.3% versus 5.8% African American). Educational 
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attainment for the sample was higher; almost half of the current sample (47.4%) had completed 
at least a Bachelor’s degree, while the same was true for just 23.4% of the older cohort from the 
Pittsburgh MSA. While generalization to other populations may be limited, the value of using 
this sample, including a set of variables derived from standardized measurement tools, is a 
critical first step to understanding who may first the first adopters of such technology. 
As hypothesized, being African American was not significantly related to being a 
Participator. The lack of racial diversity in the sample (7.3%, n=33) does limit findings and 
makes it difficult to draw firm conclusions from analysis. Many challenges to recruiting African 
Americans for study participation exist and share similarities with the challenges African 
Americans face in accessing care (Ballard, Gwyther, & Edmonds, 2010). Addressing low 
research participation for African Americans and access to care may go hand-in-hand, especially 
as results of amyloid imaging in the research setting become available. Outreach approaches for 
cognitive assessment and AD research participation recruitment continue to place focus on 
African Americans, as well as other people of color. Sharing information about the advances 
related to amyloid imaging and the growing potential for receiving results, as well as 
understanding how such a diagnostic tool is perceived by underrepresented groups is a needed 
addition to existing outreach programming and research. Social workers bring a unique expertise 
in reducing barriers to care for individuals who historically and currently have experienced 
medical disenfranchisement, and may offer intervention approaches for improving participation 
from these underrepresented groups.  
 119 
5.4 IMPLICATIONS FOR SOCIAL WORK PRACTICE 
Several implications for social work practice resulted from this dissertation that support the 
inclusion of social work practitioners in dementia care teams employing amyloid testing and 
enrich the content of amyloid imaging counseling protocols, as well as diagnostic disclosure 
protocols. In these roles, social workers may also employ advocacy skills to address the tension 
between patient and clinician views regarding the utility of amyloid imaging. 
5.4.1 Supporting and informing social work roles in amyloid imaging counseling 
protocols 
The current findings provide social workers with a first look at the biopsychosocial factors that 
impact who pursues diagnostic testing for dementia and who may be left out. These findings in 
turn inform content of AI pre- and post-counseling protocols, allowing for some insight 
regarding the factors that may be driving personal motivations or hesitancies related to testing. 
As biomarker testing including AI advances, a range of health care settings with social workers 
on staff are likely to be involved in implementing such testing. Research centers will continue to 
be a home base for AI testing, as study participants begin to gain access to test results. Other 
likely environs are geriatric clinics and primary care clinics serving significant numbers of older 
adults (Sommers, Marton, Barbaccia, & Randolph, 2000). Emerging sites for biomarker testing 
may fall under the medical home model, either adapted to focus on dementia assessment and care 
(Boustani et al., 2005) or through partnerships between primary care practices and memory 
clinics  (Callahan et al., 2006). The primary objectives of these emerging care settings are to 
 120 
improve access to screening, diagnosis, and treatment in the primary care setting, via 
multidisciplinary memory care staff, inclusive of social workers. 
Physician practices serving older adults with dementia are clearly in need of in-house 
social work for ongoing counseling and care coordination; and justification for multidisciplinary 
approaches is marked, including from the physician perspective. A study of primary care 
physicians (PCPs) serving older adults with dementia reported a lack of physician connections 
and knowledge regarding social service agencies serving IWDs and their families (Hinton et al., 
2007). One salient quote from a PCP via semi-structured interviews summarized the problem 
stating, “I am not a licensed clinical social worker” (Hinton et al., 2007, p. 1490). Cross-training 
physicians in an expertise already covered by social work practitioners becomes an inefficient 
approach, particularly when social workers are already well equipped to assess biopsychosocial 
factors that may inhibit or enhance participation in diagnostic testing, and can provide supportive 
counseling and care coordination post testing. Sharing care responsibilities across a 
multidisciplinary team, via in-house and collaborative models, will offer the best approach to 
care. 
Appropriate use criteria for AI (Johnson et al., 2013) will be a significant driver of the 
physician referral process for amyloid imaging and it will be important during counseling to 
ensure patients understand their diagnostic status and the related rationale for referral, including 
the potential medical benefit. Counseling should also incorporate a biopsychosocial model to 
explore medical, psychological, and social aspects of the individual that may impact, and be 
impacted by, the completion of AI. For instance, based on dissertation findings, AI protocols 
should specifically address concerns of more aged adults at the point of the pre-counseling stage 
and efforts should be taken to ensure that counseling approaches are not biased toward specific 
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age groups. More impaired cognition may be excluding individuals from pursuing testing. Social 
work-inclusive counseling protocols need to include supportive approaches for individuals with 
memory impairment throughout the decision-making process, applying tools that aid and assess 
understanding of discussion content. For individuals with amnestic impairments, visual aids, 
including written summaries of discussion material and providing examples of PET imaging, 
may improve understanding, as well as checks to clarify content and address questions or 
concerns (Lingler et al., 2015). Guiding familial support throughout this process will additionally 
aid in patient understanding of the decision at hand.  
A recent qualitative pilot study using a focus group to examine reactions to a hypothetical 
protocol for delivering AI results to individuals with MCI and their care partner, reported that 
participants were satisfied with the disclosure process (Lingler et al., 2015). Participants and 
specifically felt that pre-test counseling and follow-up via phone calls after receiving test results 
would enhance understanding and experience. Within the care settings noted above, social 
workers are likely to be key staff in counseling and follow-up contacts, and gaining perspective 
on factors impacting process and content for such care protocols will enhance their roles.  
5.4.2 Diagnostic transition and testing 
Participation in amyloid imaging may also be inherently tied to contact with social work 
clinicians, as change in cognitive diagnosis was significantly related to AI involvement. As noted 
previously, social workers play a primary role in the diagnostic disclosure meeting and follow-up 
care coordination. Diagnostic change can be a significant care transition for older adults and their 
families. A key tenet of social work acknowledges that patients and families experiencing care 
transitions require support and social workers have a unique and critical expertise to meet this 
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need (Herman, 2009). Health transitions put individuals at risk for additional health and 
psychosocial problems (Tahan, 2007) and acknowledging that diagnosis can present challenges 
may aid the process of identifying support needs for the patient and care partner and include a 
discussion about the utility of additional diagnostic testing. Understanding the potential 
implications of biopsychosocial factors that impact patient views on utility of testing enriches the 
conversation regarding the diagnostic change. As models of care may be moving to a merging of 
cognitive impairment disclosure, or even disclosure of the risk of cognitive impairment, with 
counseling on biomarker testing, social work roles will be of particular import. 
5.4.3 Addressing tension between personal and clinical utility 
Age at onset of memory symptoms was not a significantly associated with AI involvement, 
although individuals with early onset dementia are considered those likely to benefit from testing 
and are currently in the recommended group according to appropriate use criteria (Johnson et al., 
2013). While this dissertation did not tease out differences according to dementia diagnosis, 
where possible (not probable) AD or an atypical dementia presentation might also lead to AI 
interest - and may muddy the above finding - it does point to a potential mismatch between 
current recommendations and patient preferences. 
Tensions between the clinical and personal utilities derived from amyloid imaging do 
exist for AI (Lingler et al., 2015), and have been noted for other AD biomarkers (Roberts & 
Tersegno, 2010). Patients and families may view a benefit to be derived from completing testing, 
or personal utility even when clinical evidence recommends against testing, because testing is 
believed to lead to no medical benefit, such as a change in treatment or care management 
protocols. As a key social work value is to uphold the self-determination of the patient in care 
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decision-making (National Association of Social Workers, 2008), it naturally falls in social 
work’s purview when facilitating the AI decision-making processes to specifically advocate for 
patient preference and ensure that the patient’s views regarding testing have weight. Yet, do we 
advocate for the patient whose goal is to pursue testing when clinical utility is not believed to 
exist? Maybe we do, and our role as patient advocator may mark one of the key reasons that 
social workers need to be included in counseling processes for AI. Clinical recommendations are 
going to be in continuous change, resulting from ongoing research on the utility of AI. It may 
make a clinical difference to complete AI testing, even when current recommendations do not 
indicate one.  
Work examining the reasons individuals with first degree relatives who have AD pursue 
susceptibility genotyping for Alzheimer’s disease point to many motives that uphold personal 
utility, primarily related to planning for the future (Roberts et al., 2003). Planning for the future 
included arrangement of personal affairs and long-term care, preparing family members for the 
potential of illness, and the opportunity to complete certain activities sooner than planned 
(Roberts et al., 2003). Hence there was a clear belief that pertinent and life-altering information 
could be derived from testing beyond medical care, all of which could benefit from supportive 
counseling and care management from social workers.  
5.5 SUGGESTIONS FOR FUTURE RESEARCH 
This area is ripe for further investigation, including qualitative examinations of the motivations 
underlying AI participation, the roles of social workers in discussions related to AI testing, and 
inclusive of individuals who receive AI results. Further examination of specific cognitive 
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diagnosis, as well as varied measures of age, cognition, and health are also warranted. 
Recruitment and counseling protocols for intervention study may also be informed by the current 
findings.     
5.5.1 Qualitative investigation 
Applying qualitative methods to future research exploring interest in amyloid imaging is 
definitely warranted. A first step might include semi-structured interviews with individuals (and 
their care partners) from the current sample, and drawn from each AI interest grouping. To 
inform social work practice in particular and build from the findings of this study, interview 
guide content could focus on question structures exploring underlying motivations, and aspects 
of personal and clinical utility attached to participation. Triangulation with data from the current 
study could explore thematic links to biopsychosocial factors.  
As there is a growing group of patients who have completed amyloid imaging and 
received results from testing at the ADRC, a mixed methods study derived from this group could 
include qualitative interviews with patients and care partners. The study sample should include 
individuals who elected to complete AI, and a sample of individuals who declined. Data 
extraction from the ADRC could pair interviews with biopsychosocial factors to explore 
thematic links and better inform social work practice. This work might also reveal any potential 
differences that exist between willingness to complete testing and willingness to receive results. 
Longitudinal follow-up with patients and families, via interviewing and ADRC data extraction, 
could aid in our understanding of whether the personal and clinical utilities anticipated to be 
derived from AI participation, come to fruition, in comparison to those who decline AI testing. 
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Finally, those experiencing diagnostic change were more likely to participate in AI. 
Qualitative investigation of the content of discussions during diagnostic meetings, often 
facilitated by a social worker and clinician, and inclusive of patients and one more or more 
family member(s), might further inform our understanding of motivations related to AI 
participation. The voiced discussion content of diagnostic disclosure meetings for cognitive 
impairment has not been well examined and has primarily focused on emotional response to 
diagnosis (Aminzadeh, Byszewski, Molnar, & Eisner, 2007), rather than care planning and 
health care use following disclosure, or the roles of clinical staff in such meetings. This 
qualitative approach may also enrich our understanding of the roles that social workers play in 
facilitating decision-making related to AI testing.  
5.5.2 Diagnostic and AD family history groupings 
As this dissertation provided an initial look at how participation in AI research, examining 
whether diagnostic grouping was significantly associated with AI interest and participation was 
important to include. Individuals with dementia were examined separately as they comprise the 
diagnostic group that has historically been the focus of AI testing. From a clinical perspective, 
understanding how significant factors differ by diagnosis offers a pathway to more nuanced 
discussions with patients, that take into account diagnostic status and related factors that may be 
important. ADRC diagnosis significantly differed between AI interest groups, yet this significant 
relationship did not hold in multivariate analysis. Individuals with dementia had higher 
percentages of Refusers than Participators, while those diagnosed with MCI had more 
representation among Participators than in the Refusers or Avoiders groups. Interestingly, 
individuals with no cognitive impairment represented a greater proportion of Avoiders, than 
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Participators or Refusers. Future work should examine the relationship between diagnostic 
grouping and AI interest particularly among subsamples of individuals with MCI or no cognitive 
impairment. Both groups had greater percentages of Participators overall, and, as was noted for 
IWDs, the biopsychosocial factors driving AI interest and participation are likely to differ from 
the current sample that included varying cognitive diagnoses. For example, in the current sample 
and the subset of IWDs, presence of a psychiatric diagnosis was not related to AI interest, as 
hypothesized. However, completing similar multivariate modeling with a sample diagnosed with 
MCI may present a different picture because, although psychiatric symptoms more commonly 
co-occur with dementia rather than MCI (Lyketsos et al., 2002), psychiatric diagnosis may be 
predictive of progression to dementia from MCI (Palmer et al., 2007), and may enhance interest 
in AI testing that elucidates the underlying disease process. 
Additionally, drilling down to more specified diagnoses is warranted, and should focus 
on the diagnostic groups specified by appropriate use criteria. AUC points to several 
recommended diagnostic groups: 1) individuals with persistent or progressive unexplained MCI; 
2) individuals diagnosed with possible AD (rather than probable AD) with an atypical course or 
a mixed presentation; and 3) individuals with early onset dementia (age 65 years or younger at 
onset) (Johnson et al., 2013). This would likely require a larger sample than that used for this 
dissertation, and could be derived from multiple Alzheimer Disease Centers, improving 
generalizability. For comparison, an analysis of diagnoses for which there is no recommendation 
would aid in characterizing who may still view a utility to be gained from testing, when no 
medical benefit is present.  
Having a first degree relative with dementia was not significantly related to AI interest 
and participation. Alternative measures of dementia family history, such as AD genetic 
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susceptibility status or number of family members with dementia (Lautenschlager et al., 1996), 
may serve as better indicators of AI involvement. As with cognitive diagnostic groupings, 
examining whether biopsychosocial factors related to AI participation differ by presence or 
absence of dementia family history might also tease out differences between groups.  
5.5.3 Further examination of age, race, cognition, and health 
Several significant factors, age, cognition, and physical health comorbidity, identified in this 
dissertation warrant further examination via alternative measurement approaches. Modeling age 
groups may further demarcate the age range most associated with AI, or a cutpoint at which age 
becomes significantly related to amyloid testing. Expanding sampling to the national UDS 
dataset may allow for better representation of people of color. The NACC UDS includes a 
detailed question structure to gain data on race and ethnicity, allowing for a deeper dive into this 
examination. The cognition measure used in this dissertation, Mini Mental State Exam score, is a 
generalized measure; more specified, single-domain neuropsychological measures of memory or 
executive functioning, among others, might better tease out what aspects of cognitive functioning 
may be impacting decision-making related to AI. Lastly, measurement of medical comorbidity 
was limited by data available from the ADRC, via the NACC UDS. More detailed examination 
of health status, including medical comorbidities also considered risk factors for dementia (e.g. 
diabetes, cardiovascular disease) and health behaviors (e.g. smoking, alcohol use, exercise, 
advance care planning) that might relate to AI interest, might further characterize who is seeking 
testing. These more delineated characterizations will better inform pre and post-counseling 
approaches for AI.    
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5.5.4  Intervention studies  
Work is underway to test approaches for disclosing amyloid imaging results to individuals with 
no cognitive impairment (Harkins et al., 2015; Karlawish et al., 2013), and individuals diagnosed 
with MCI (Lingler, Roberts, Schulz, & Klunk, 2012; Lingler et al., 2015), in research settings. A 
large, multi-site study will begin in 2016 to examine whether a medical benefit is derived from 
AI testing adapted to clinical practice for individuals meeting AUC (Zakaid, 2015). Tailoring 
study recruitment protocols, for example using sampling quotas to address a potentially low yield 
of certain subgroups (i.e. the older old), and incorporating intervention materials to be tested to 
address biopsychosocial factors that impact personal utility related to AI may aid in improving 
study outcomes.  
5.6 CONCLUSIONS 
This study examined biopsychosocial factors related to interest and participation in amyloid 
imaging for the diagnosis of dementia. A second set of analyses examined factors associated 
with amyloid imaging interest and participation for a subsample of individuals with dementia. 
For the full sample, younger age, better cognition, and experience of cognitive diagnostic change 
were related to both AI interest and participation when controlling for sex, race, education, 
medical comorbidity, psychiatric diagnosis and dementia family history. For the subsample of 
IWDs, absence of medical comorbidity and having a spousal or partner relationship providing 
informal care support were associated with AI interest and participation, when controlling for 
demographics (age, sex, race, and education level), cognition, age at onset of cognitive 
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symptoms, psychiatric diagnosis, and dementia family history. The significance of experiencing 
a cognitive diagnostic transition points to the importance of social workers in facilitating 
amyloid imaging participation. The finding that the “younger-old” were more likely to agree to 
AI than the “older-old” may relate to a greater interest among “young-older” adults to be more 
active participants in their health, yet points to a need for social workers to address participation 
among the “older-old”. Better cognition, potentially a proxy for better decisional ability, implies 
a need for social workers to ensure counseling protocols for AI are easily understandable for 
individuals with memory impairment, or that supportive decision-making is provided by family 
members. For individuals with dementia, medical comorbidity and related health concerns may 
create a barrier to seeking AI, while the significance of spousal and partner care relationships 
intimates that these care partners have more time and interest to devote to amyloid imaging. 
These findings support social work roles in multidisciplinary dementia care teams using amyloid 
imaging, as well as other biomarker tests for AD, and enrich the content of AI counseling 
protocols by identifying factors impacting motivations to participate in AI.  
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